The QualityStocks Daily Stock List
- Salarius Pharmaceuticals (SLRX)
- Quotient (QTNT)
- PetVivo Holdings (PETV)
- Better Choice Company (BTTR)
- KemPharm (KMPH)
- iCAD Inc. (ICAD)
- Terawulf Inc. (WULF)
- Akanda Corp (AKAN)
- Firsthand Technology Value Fund (SVVC)
- VNET Group (VNET)
- Warrior Met Coal Inc. (HCC)
- Fisker Inc. (FSR)
Salarius Pharmaceuticals (SLRX)
StockMarketWatch, QualityStocks, Stocks That Move and MarketBeat reported earlier on Salarius Pharmaceuticals (SLRX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Salarius Pharmaceuticals Inc. (NASDAQ: SLRX) (FRA: FP11) is a clinical stage biotechnology firm that is engaged in the development of cancer treatments that are epigenetic-based. Epigenetic refers to the regulatory system that influences gene expression.
Salarius Pharmaceuticals Inc. operates in the biotechnology industry, under the healthcare sector and is based in Houston, Texas. The firm, which was known as Flex Pharma Inc. before changing its name has been granted Product Development Award funding that totals $18.7 million by the Cancer Prevention and Research Institute of Texas in addition to other funding by the National Pediatric Cancer Foundation for the advancement of the Ewing sarcoma clinical program. Salarius Pharmaceuticals Inc. serves consumers and patients in the U.S. and was established in 2014.
Salarius Pharmaceuticals is party to strategic partnerships with the Cancer Prevention and Research Institute of Texas for various activities that entail product development; HLB Life Sciences for the development, manufacture, production and sale of the SP-2577 candidate in South Korea and the University of Utah Research Foundation for the license to patent rights that protect SP-2577 and associated compounds.
Salarius Pharmaceuticals Inc.’s product pipeline includes its lead candidate; seclidemstat, which is undergoing a phase 1/2 clinical trial for relapsed or refractory Ewing sarcoma. The candidate, which is also known as SP-2577, is also undergoing phase 1/2 clinical trials that evaluate its efficacy in treating advanced solid tumors, including ovarian, breast and prostate cancers.
As of 2020, the firm’s SP-2577 candidate had been awarded Rare Pediatric Disease Designation, Orphan Drug Designation and Fast Track Designation by the FDA. Seclidemstat employs a new approach to treat/improve Ewing sarcoma, which will not only benefit patients by addressing a previously unmet medical need but also extend the firm’s reach in the market, which will be good for its growth and investment opportunities.
Salarius Pharmaceuticals (SLRX), closed Thursday's trading session at $0.2368, up 14.6731%, on 3,169,505 volume. The average volume for the last 3 months is 3.17M and the stock's 52-week low/high is $0.1599/$1.20.
Quotient (QTNT)
TraderPower, StockMarketWatch, Marketbeat, MarketClub Analysis, Barchart, StocksEarning, QualityStocks, BUYINS.NET, Marketbeat.com, Trading Concepts, The Stock Dork, InvestorsUnderground, Investing Futures, Daily Trade Alert and Daily Market Beat reported earlier on Quotient (QTNT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Quotient Ltd. (NASDAQ: QTNT) (FRA: U4W) is a commercial-stage diagnostics firm that is engaged in the development, manufacture and sale of transfusion diagnostic products which focus on serological disease screening and blood grouping in Japan, France, the United States and also, internationally.
The company has its headquarters in Eysins, Switzerland and was incorporated in 2007. It operates in Newton, Pennsylvania; Eysins, Switzerland, Scotland and Edinburgh but derives most of its revenue from the United States.
The firm sells its products to blood banking operations, original equipment manufacturers, independent testing laboratories, donor collection agencies, hospital and other diagnostics firms. Its product portfolio includes specialty kits, specialty products, Antisera and red cell reagents.
The enterprise has developed a proprietary technology platform that offers tests for serological and immunohematology disease screening, dubbed MosaiQ. The company’s standard reagent products for blood grouping include ancillary products that support blood grouping; whole blood control products indicated for daily quality assurance tests; reagent red blood cells which allow blood group antibodies to be identified and antisera products that are utilized in the identification of blood group antigens. The company is also developing a SARS-CoV-2 antibody test, which is micro-array based and will be used on the MosaiQ platform for coronavirus.
The company recently won a Red Dot Product Design Award for its MosaiQ system, which has been designed to deliver rapid molecular, serological and immunohematology disease screening. The award stands as a testament to the company’s design and creativity efforts and shows just how much of an impact the company has made in transfusion diagnostics. Additionally, the firm’s MosaiQ Covid-19 Antibody Microarray recently received the FDA’s emergency use authorization. These moves by the firm are bound to bring in more investors, which will not only help push their stock prices higher but also boost their growth.
Quotient (QTNT), closed Thursday's trading session at $0.2074, up 13.2096%, on 8,407,668 volume. The average volume for the last 3 months is 6.373M and the stock's 52-week low/high is $0.16/$3.185.
PetVivo Holdings (PETV)
EmergingStockPlays, PennyStocks24, ExclusiveStockPick, VipStockReports, QualityStocks, SmallCapInvestorDaily, OTCtipReporter, PennyStockScholar, Bull Trends, Pumps and Dumps, Jet-Life Penny Stocks, Penny Pick Insider, Penny Stocks VIP, Equity Observer, Wall Street Mover, Daily Stock Motion, PoliticsAndMyPortfolio, Planet Penny Stocks, PennyStockProphet, Penny Stocks Profile, PennyStockShark, Penny Pick Finders, OTCBB Journal, Michael Stone, HotStockProfits, Growing Stocks Reports, First Penny Picks, Featured PS Report, Epic Stock Picks, DSR News, Club Penny Stocks Network, Buzz Stocks, MajorPennyStocks, Stock News Now, Value Penny Stocks, Wallstreetbuzz, Trading Wall St, Research Driven Investor, Research Driven Alerts, Super Hot Penny Stocks, Hot Stock Profits, Super Nova Stock Picks, InvestorSoup, JackpotStock Picks, TopPennyStockMovers, Goldman Small Cap Research, FOX Penny Stocks, Fortune Penny Stocks, SuperStockTips, The Lotto Pick, Greenbackers, Trades Of The Day, Super Hero Stocks, USA Market News, LuckyStockPicks, Email Stock Picks, Damn Good Penny Picks, Wallstreet Profiler, WePickPennyStocks, Winning Penny Stock Picks, Breaking Bulls, Blaque Capital Stocks, Beacon Equity Research, AwesomeStocks, EpicVIP Group, Penny Stock Pick Alert, Psycho Penny Stocks, PREPUMP STOCKS, RisingPennyStocks, SecretStockPromo, SixFigureStockPicks, SMS Penny Picks, PennyStock PayCheck, PennyStock MarketBulls, PennyPickAlerts, Xtreme Stock Picks, Stock Preacher, Ascending Stocks, Joe Penny Stocks, Penny Stock Pick Report and PennyDoctor reported earlier on PetVivo Holdings (PETV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
PetVivo Holdings Inc. (NASDAQ: PETV) is a biomedical device and veterinary biotech firm that is focused on the licensing and commercialization of biomaterials and medical devices used to treat ailments and afflictions in companion animals like horses and dogs.
The firm has its headquarters in Minneapolis, Minnesota and was incorporated in 2009, on March 31st by John F. Dolan and John Lai. It serves consumers in the state of Minnesota and the United States at large.
PetVivo Inc., which is the company’s operating subsidiary, is involved in the acquisition and adaptation of human biomedical products and technology for commercial sale in the veterinary market to treat pets and other animals which suffer from painful ailments like arthritis. The company’s other subsidiary, Gel-Del Technologies Inc., has concluded a pivotal clinical trial which used their thermoplastic biomaterials as a dermal filler for cosmetic applications in humans.
The enterprise’s product pipeline is made up of more than 15 therapeutic devices for human and veterinary clinical applications. These include VD-04, which has been developed to treat urinary incontinence; VD-06 and VD-02, which have been developed for osteoarthritis management. Its lead product is an intra-articular joint injection dubbed Kush, which contains patented, gel-like biomaterials. It is indicated for the treatment of lameness and osteoarthritis in horses and dogs and is usually administered by veterinarians.
The company recently appointed a new national director of sales who has extensive experience in distribution and manufacturing in the animal health industry. This move will be good for the company, whose objective for success is growing its sales.
PetVivo Holdings (PETV), closed Thursday's trading session at $2.79, up 15.7676%, on 54,627 volume. The average volume for the last 3 months is 54,627 and the stock's 52-week low/high is $1.20/$5.14.
Better Choice Company (BTTR)
QualityStocks, RedChip, PoliticsAndMyPortfolio, Weekly Newsletter, Red Chip and MarketBeat reported earlier on Better Choice Company (BTTR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Better Choice Company Inc. (NYSE American: BTTR) is an animal health and wellness firm which is focused on the provision of premium treats, foods and supplements for animals.
The firm has its headquarters in Oldsmar, Florida and was incorporated in 2001, on January 3rd. It operates as part of the other miscellaneous store retailers’ industry. The firm has five companies in its corporate family and serves consumers in Asia, Australia, Canada and the United States.
The company takes a nutrition-based alternative approach to animal health relative to conventional cat and dog food offering. It is focused on positioning its portfolio of brands to benefit from consumer focus on health and wellness and mainstream trends of increasing pet humanization. The company is committed to leading the industry shift toward pet services and products that help cats and dogs live longer, happier and healthier lives.
The enterprise provides vegan dog treats and food, freeze-dried raw dog treats and food, canned cat and dog food, naturally formulated premium kibble, raw-diet dog treats and food, supplements, oral care products and grooming aids. It offers its products for cats, dogs and pet parents under the Rawgo! TruDog and Halo brand name. The enterprise mainly sells its products through pet specialty stores and online retailers, as well as through its online portal.
The company recently entered into a nationwide distribution agreement with Phillips Pet Food & Supplies, to launch a new natural pet food brand known as Halo Elevate. This move will facilitate the delivery of Better Choice’s high quality pet products and food across Phillips’ extensive distribution network, which will help extend the company’s consumer reach and bring in additional revenue.
Better Choice Company (BTTR), closed Thursday's trading session at $1.68, up 19.1489%, on 198,770 volume. The average volume for the last 3 months is 198,570 and the stock's 52-week low/high is $1.30/$4.30.
KemPharm (KMPH)
Schaeffer's, MarketBeat, StockMarketWatch, QualityStocks, Barchart, TraderPower, StreetInsider, Trading Concepts, Streetwise Reports, StocksEarning, Marketbeat.com, Investing Futures, INO.com Market Report, Daily Trade Alert and BUYINS.NET reported earlier on KemPharm (KMPH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
KemPharm Inc. (NASDAQ: KMPH) (FRA: 1GDA) is a specialty pharmaceutical firm that is focused on the discovery and development of different proprietary pro-drugs for the treatment of severe medical indications.
The firm has its headquarters in Celebration, Florida and was incorporated in 2006, on October 30th. It operates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm has three companies in its corporate family and serves consumers in the United States.
The company engages in discovery and development of therapies for treating a myriad of indications. It is party to a number of collaboration and license agreements with Commave Therapeutics SA and KVKTech Inc. The company uses its Ligand Activates Therapy technology to develop improved versions of drugs which have already been approved by the FDA.
The enterprise’s candidate pipeline focuses on high need areas of central nervous system rare illnesses, stimulant use disorder and ADHD (attention deficit hyperactivity disorder). It comprises of a pro-drug candidate dubbed KP879, which has been developed to treat stimulant use disorder; and its KP1077 formulation which is undergoing phase 2 clinical trials testing its efficacy in treating narcolepsy and idiopathic hypersomnia. The KP1077 candidate is based on a d-methylphenidate pro-drug dubbed serdexmethylphnidate.
The company is currently focused on advancing the development of its KP1077 formulation. The success and approval of this formulation by the FDA for the treatment of idiopathic hyperinsomnia will not only bring in additional investments and revenues into the company but also bolster the company’s growth.
KemPharm (KMPH), closed Thursday's trading session at $6.85, up 12.6645%, on 421,968 volume. The average volume for the last 3 months is 421,968 and the stock's 52-week low/high is $4.00/$10.7994.
iCAD Inc. (ICAD)
MarketBeat, Wall Street Resources, Trading Concepts, TraderPower, BUYINS.NET, SmarTrend Newsletters, InvestorPlace, QualityStocks, StreetInsider, The Online Investor, FeedBlitz, HotOTC, Marketbeat.com, CoolPennyStocks, MicrocapVoice, Chart Topper, PennyStockVille, MadPennyStocks, Sling-Shot-Stocks, StockEgg, StockMarketWatch, StockRich, Street Insider, Streetwise Reports, The Street, TheStockAdvisors, Top Secret Stocks, Trade of the Week and SmallCapVoice reported earlier on iCAD Inc. (ICAD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
iCAD Inc. (NASDAQ: ICAD) is a medical technology firm that is engaged in the provision of image analysis, radiation therapy and workflow solutions for the treatment of cancer.
The firm has its headquarters in Nashua, New Hampshire and was incorporated in 1984. Prior to its name change in June 2022, the firm was known as Howtek Inc. It operates as part of the medical devices industry, under the healthcare sector. The firm serves consumers in the United States.
The enterprise operates through the cancer therapy and cancer detection segments. Its offerings include a machine learning-based cancer detection algorithm known as SecondLook, which analyzes full-field 2D digital mammography images to identify suspicious calcifications and masses; and a deep-learning algorithm dubbed ProFound AI, which has been designed to detect malignant soft-tissue calcifications and densities in digital breast tomosynthesis. It also offers automated density assessment solutions, which offer standardized, consistent and automated density assessments; a tool known as ProFound AI Risk, which offers breast cancer risk estimation based on a mammogram; and an MRI tool for the detection of prostate and breast cancer. In addition to this, the enterprise provides XoftAxxent electronic brachytherapy systems for the treatment of gynecological, non-melanoma skin and early stage breast cancers, to cancer care clinics, dermatology offices, community and university research hospitals.
The company recently announced its latest financial results, which show an increase in revenue generated in its cancer detection segment. It remains focused on using its flexible subscription and cloud-based models to expand access to its technologies, which will help generate additional revenues for the company.
iCAD Inc. (ICAD), closed Thursday's trading session at $2.49, off by 7.7778%, on 124,236 volume. The average volume for the last 3 months is 124,157 and the stock's 52-week low/high is $2.45/$12.60.
Terawulf Inc. (WULF)
MarketBeat and InvestorPlace reported earlier on Terawulf Inc. (WULF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
TeraWulf Inc. (NASDAQ: WULF) is a digital asset technology firm that is focused on operating and owning fully integrated environmentally clean bitcoin mining facilities.
The firm has its headquarters in Easton, Maryland and was incorporated in 2021, on February 8th. It operates as part of the capital markets industry, under the financial services sector. The firm serves consumers in the United States.
The infrastructure-focused bitcoin mining company is focused on accelerating the transition to a zero-carbon future. Its goal is that every kwH of energy consumed will be generated from a zero carbon source of energy. The company conducts its business operations through its subsidiaries, including Lake Mariner Data LLC, Nautilus Cryptomine LLC, Kyalami Data LLC, TeraWulf Brookings LLC, TeraWulf LLC and TeraWulf Ploughwind LLC.
The enterprise develops, operates and owns bitcoin mining facilities powered by nuclear, hydro and solar energy. It has 2 industrial-scale mining facilities, which are located in Pennsylvania and New York. The facilities in question, the Nautilus Cryptomine facility and the Lake Mariner facility, mine bitcoin using cost-effective zero-carbon energy. These bitcoin mining sites have over 23 exahash per second (EH/s) of computational power and about 800 MW of gross bitcoin mining capacity.
The firm recently released its latest financial results, with its CEO noting that they remained committed to its vertical integration and zero-carbon strategy, managing its assets sustainably and outperforming the industry going forward. This will help differentiate it from other players in the field and drive investments into the firm.
Terawulf Inc. (WULF), closed Thursday's trading session at $1.16, even for the day, on 285,717 volume. The average volume for the last 3 months is 281,225 and the stock's 52-week low/high is $1.06/$43.98.
Akanda Corp (AKAN)
Schaeffer's and PennyStockProphet reported earlier on Akanda Corp (AKAN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Akanda Corp (NASDAQ: AKAN) (FRA: Y23) is a global medical cannabis cultivation, manufacturing and distribution firm involved in manufacturing and distributing medical cannabis products to patients.
The firm has its headquarters in New Romney, the United Kingdom and was incorporated in 2021, on July 16th. It operates as part of the drug manufacturers-specialty and generic industry, under the healthcare sector. The firm serves consumers around the globe, with a focus on those in Lesotho and the United Kingdom.
The company is on a mission to heal the future by providing high-quality, ethically sourced medical cannabis and wellness products to patients around the globe. It seeks to drive positive change in wellness while limiting its carbon footprint. The company’s subsidiaries include Holigen Ltd, Cannahealth Ltd, Bophelo Holdings Ltd, Canmart Ltd and Bophelo Bio Science and Wellness Ltd.
The enterprise is building a seed-to-patient supply chain which connects patients in Europe and the UK with diverse cannabis products. It grows and processes natural cannabis at its grow facilities, which are located in Portugal and the Kingdom of Lesotho. It intends to supply cannabis flower, medicinal-grade cannabis biomass and cannabis concentrates to wholesalers in global markets. The enterprise also intends to import and sell medical cannabis-based products to the domestic market in the UK.
The firm recently entered into an exclusive license agreement with Cookies, a global cannabis lifestyle brand. This agreement will allow the firm to pursue medical and adult-use opportunities in Europe, which will not only extend its reach globally but also open it up to new growth opportunities. This will in turn help generate significant shareholder value.
Akanda Corp (AKAN), closed Thursday's trading session at $0.67, off by 2.5171%, on 134,184 volume. The average volume for the last 3 months is 133,404 and the stock's 52-week low/high is $0.65/$31.00.
Firsthand Technology Value Fund (SVVC)
Wealth Daily, The Motley Fool, StreetInsider, StreetAuthority Daily, StockMarketWatch, Money and Markets, InvestorPlace and HotStockProfits reported earlier on Firsthand Technology Value Fund (SVVC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Firsthand Technology Value Fund Inc. (NASDAQ: SVVC) (MUTF: TEFQX) is a business development firm that specializes in venture capital investments in start-up, early stage, early development stage, middle stage, late stage and PIPEs.
The firm operates as part of the asset management industry, under the financial services sector. It serves consumers around the globe.
The enterprise’s primary focus is to invest in illiquid private tech and cleantech firms. It invests in private technology, IT, clean-tech sector and other firms which possess patents and other defensible intellectual property rights with a focus on computer hardware, consumer electronics, the Internet, computer software, computer peripherals, social networking, energy efficiency, solar photovoltaic, electronic components, bio-fuels, fuel cells, semiconductors and advanced materials. It also seeks to invest in pre-IPO firms as well as in micro-cap publicly traded companies. This is in addition to making investments in connection with the divestiture or acquisition of firms or divisions of firms. The enterprise primarily invests in equity securities of private firms in the U.S. It invests through negotiations with selling shareholders, direct investments in private firms and in organized secondary marketplaces for private securities. It structures its equity investments as common stock, preferred stock, options, limited partnership interests, warrants, high-yield bonds, other beneficial ownership interests, distressed debt, short-term debt investments and convertible debt.
The company, which recently announced its latest financial results, remains focused on seeking long-term growth of capital, primarily by seeking capital gains on its equity and equity-related investments. This will drive investments into the firm and help generate value for its shareholders.
Firsthand Technology Value Fund (SVVC), closed Thursday's trading session at $1.4, up 2.1898%, on 7,025 volume. The average volume for the last 3 months is 7,025 and the stock's 52-week low/high is $1.36/$5.31.
VNET Group (VNET)
StocksEarning, MarketBeat, StreetInsider, MarketClub Analysis, INO.com Market Report, The Street, StockEarnings, Marketbeat.com, Barchart, Zacks, BUYINS.NET, PennyOmega, PennyToBuck, DrStockPick, Hit and Run Candle Sticks, StockHotTips, StockMarketWatch, CRWEPicks, Street Insider, CRWEFinance, TraderPower, TradersPro, BestOtc, CRWEWallStreet, FeedBlitz, Schaeffer's, FreeRealTime, GreatStockPix, Rick Saddler, SmallCapVoice, SmarTrend Newsletters, Stock Tips Network, Stocks That Move, TheStockAdvisors, Trades Of The Day, WealthMakers and Profit Confidential reported earlier on VNET Group (VNET), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
VNET Group Inc. (NASDAQ: VNET) (FRA: 217A) is an investment holding firm that is engaged in the provision of hosting and related services.
The firm has its headquarters in Beijing, China and was incorporated in 1999, on October 16th by Jun Zhang and Sheng Chen. Prior to its name change in October 2021, the firm was known as 21Vianet Group Inc. It operates as part of the information technology services industry, under the technology sector. The firm serves consumers in the People’s Republic of China.
The enterprise provides managed hosting services comprised of managed retail services, such as interconnectivity services that enable clients to connect to their servers; colocation services that dedicate data center space to house clients' servers and networking equipment; value-added services, including server load balancing, hybrid IT, data center management, data backup and recovery, and backup server services; server administration services; VPN services which extend consumers' private networks by setting up connections through the public internet; and cloud services which enable clients to run applications over the internet using IT infrastructure. The enterprise also offers operating system support and assistance with updates, firewall services, server security evaluation, server monitoring and server backup and restoration; and construction services for retail and wholesale data centers. It serves IT and cloud services, social networking and communications, and telecommunication carriers.
The company, whose latest financial results show increases in its net revenues, remains focused on building its customer base across more industries and maximizing on its opportunities. This will not only bring in additional investments and revenues into the company but also help create value for its shareholders.
VNET Group (VNET), closed Thursday's trading session at $6.1, up 0.164204%, on 2,428,158 volume. The average volume for the last 3 months is 2.428M and the stock's 52-week low/high is $3.51/$19.89.
Warrior Met Coal Inc. (HCC)
MarketBeat, The Online Investor, StreetInsider, INO.com Market Report, QualityStocks, Zacks, The Street, Trades Of The Day, Daily Trade Alert, BUYINS.NET, StockMarketWatch, MarketClub Analysis, Schaeffer's, StreetAuthority Daily, AllPennyStocks, Market Intelligence Center Alert, InvestorPlace, Street Insider, CRWEFinance, TopStockAnalysts and SmarTrend Newsletters reported earlier on Warrior Met Coal Inc. (HCC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Normally, late July and early August are the wettest months in southern China. This year, however, rainfall during this period was below normal with precipitation in the region since July remaining at 135 mm. This is significantly lower than the average annual precipitation of the region from 2014 to 2021, which stood at 464 mm.
This drought has prompted an increase in the price of coal, as traders expect that more coal will be burned to meet the demand for electricity this winter as hydroelectric power generation dwindles.
The country’s increasing consumption of coal may worsen the already present global shortage as producers of power in the United States and Europe also revert back to the use of the fossil fuel as gas prices increase.
The shift observed in China marks a turn from earlier in the year when abundant hydro generation and heavy rainfall enabled the country to reconstruct depleted inventories and decrease its use of coal. During the first seven months of this year, China generated almost 730 billion kilowatt-hours of hydroelectricity, an amount significantly higher than its prior-2019 record of 650 billion kilowatt-hours.
This increase in hydroelectric power generation can mainly be attributed to the rainfall southern China received, which is said to be its highest since 2016. Total precipitation in the region amounted to about 687 mm.
During this period, China also recorded considerable increases in power generated from solar and wind, 28 and 61 billion kilowatt-hours respectively. This is in addition to recording a slight increase in output from nuclear, which amounted to 3 billion kilowatt-hours.
Data from the country’s National Bureau of Statistics shows that with more than enough electricity from other energy sources, power generation from coal-fired plants reduced by more than 60 billion kilowatt-hours. Currently, hydroelectric power generation may likely remain low through the rest of the year and well into next year.
To make up for this shortfall, China will need to up its consumption of coal, which will in turn put more pressure on stocks. For instance, Zhengzhou Commodity Exchange’s most actively traded domestic futures contract recently reached $148 per ton. This is its highest price in almost a year, increasing from $125 in June.
This increase is also making long rail journeys from the coal fields located in the north to power generators in the south even more frequent. It is expected that the tightening coal supply in China will affect global prices greatly as the nation accounts for more than one-half of total consumption globally. Coal producers such as Warrior Met Coal Inc. (NYSE: HCC) are likely to record even greater profit margins if prices rise any higher than their current levels.
Warrior Met Coal Inc. (HCC), closed Thursday's trading session at $28.6, off by 4.2197%, on 688,961 volume. The average volume for the last 3 months is 658,899 and the stock's 52-week low/high is $20.251/$42.95.
Fisker Inc. (FSR)
InvestorPlace, Schaeffer's, StocksEarning, MarketClub Analysis, MarketBeat, Kiplinger Today, The Street, The Online Investor, Trades Of The Day, Daily Trade Alert, QualityStocks, TradersPro, Early Bird, StreetInsider, TipRanks, wyatt research newsletter, Cabot Wealth, InvestorsUnderground and CNBC Breaking News reported earlier on Fisker Inc. (FSR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Electric vehicle batteries have been subject to constant research and improvements over the past couple of years to improve their energy density and safety. Although high-end electric vehicles can have up to 400 miles in range on a single charge, the average EV doesn’t have enough range to alleviate range anxiety. And given that America’s public charging infrastructure is woefully insufficient, many people are reluctant to switch to battery-powered electric cars.
Solid state batteries, which replace the traditional liquid electrolyte in lithium-ion batteries with a solid electrolyte and use lithium metal anodes rather than a graphite anode, are slated to be game changers in EV battery technology. They are more energy dense, which gives them significantly increased range, and they are much more resistant to overheating and fires. Experts predict that solid-state batteries could be the catalyst that finally tips the scales in favor of electric cars and leads to mass adoption.
But despite the lofty predictions of solid-state batteries dominating the EV battery segment in the near future, Prime Planet Energy & Solutions president Hiroaki Koda says that lithium-ion batteries will be king for the next decade. Prime Planet Energy & Solutions is a joint venture between Panasonic and Toyota that currently develops square lithium-ion batteries.
As the race to electrification heats up, automakers are investing millions of dollars into developing solid-state EV batteries because they promise to bring enhanced safety and extended range. Ford and Volkswagen invested in solid-state battery companies Solid Power and Quantumscape, Nissan has announced plans to mass produce solid-state batteries by 2028, and Honda will use $301 million to operate a pilot production line for the novel battery technology.
Solid state batteries may be a game changer, but their time is not now, Koda said, stating that there are a few things preventing these batteries from becoming prevalent in the near future. For starters, he said, solid-state batteries are complex and challenging to develop, a factor that could slow down their development. Koda also said that the dominance of these batteries may be held back by new developments in lithium-ion battery chemistries.
Research company Strategy Analytics is of the same opinion, predicting that the deployment of solid-state batteries will be delayed until the end of the decade.
At the moment, EV makers such as Fisker Inc. (NYSE: FSR) are looking for innovative ways to maximize value from the current battery technology in use so that motorists enjoy reliable and cost-effective fully electric vehicles in the push to phase out vehicles running on fossil fuels.
Fisker Inc. (FSR), closed Thursday's trading session at $9.15, off by 0.866739%, on 14,967,245 volume. The average volume for the last 3 months is 14.81M and the stock's 52-week low/high is $7.95/$23.75.
The QualityStocks Company Corner
- D-Wave Quantum Inc. (NYSE: QBTS)
- Lexaria Bioscience Corp. (NASDAQ: LEXX)
- Knightscope Inc. (NASDAQ: KSCP)
- HeartBeam Inc. (NASDAQ: BEAT)
- Freight Technologies Inc. (NASDAQ: FRGT)
- Mullen Automotive Inc. (NASDAQ: MULN)
- CNS Pharmaceuticals Inc. (NASDAQ: CNSP)
- Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF)
- Silo Pharma Inc. (OTCQB: SILO)
- EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF)
- Correlate Infrastructure Partners Inc. (OTCQB: CIPI)
- Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF)
D-Wave Quantum Inc. (NYSE: QBTS)
The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).
D-Wave Quantum Inc. (NYSE: QBTS), a leader in quantum computing systems, software, and services—and the only provider building both annealing and gate-model quantum computers, today published a peer-reviewed milestone study of the first large-scale demonstration of coherent quantum annealing. The research exhibits, for the first time, dynamics of a quantum phase transition in a large-scale programmable quantum annealing processor using up to 2000 qubits in a D-Wave processor. This demonstration goes beyond the scale of any previous programmable quantum phase transition, opening the door to simulations of exotic phases of matter (unusual states of matter, outside of liquid, solid or gas, that make up the universe) that would otherwise be intractable. The paper---a collaboration between scientists from D-Wave, the University of Southern California, the Tokyo Institute of Technology, and Saitama Medical University---entitled “Coherent quantum annealing in a programmable 2000-qubit Ising chain,” was published in the peer-reviewed journal Nature Physics today and is available here . The study shows that the fully programmable D-Wave quantum processor can be used as an accurate simulator of coherent quantum dynamics at large scales. This was demonstrated showing the patterns of “kinks” separating correlated spins in almost perfect agreement with exact analytical solutions of the famous Schrodinger equation for an ideal quantum system, completely isolated from outside noise. The density and spacing of kinks depend on, among other things, the speed and “quantumness” of the experiment. Measurements of single-qubit parameters were shown to accurately predict the behavior of systems from 8 to 2000 qubits, demonstrating high levels of control in quantum simulations at all scales.
D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.
D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).
D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.
D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.
Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.
Advantage™ Quantum Computer
With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.
D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.
That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.
Leap Quantum Cloud Service
D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.
Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.
Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.
D-Wave Launch
D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.
From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.
Target Verticals
While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:
- Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
- Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
- Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.
Market Opportunity
The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.
Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.
D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.
D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.
Leadership Team
Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.
John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.
D-Wave Quantum Inc. (NYSE: QBTS), closed Thursday's trading session at $8.32, up 6.6667%, on 283,051 volume. The average volume for the last 3 months is 279,044 and the stock's 52-week low/high is $5.40/$13.23.
Recent News
- D-Wave Quantum Inc. (NYSE: QBTS) - D-Wave Demonstrates Large-Scale Coherent Quantum Annealing
- 7 Quantum Computing Stock Picks to Beat the September Market SlumpMore From InvestorPlace
- InvestorNewsBreaks - D-Wave Quantum Inc.'s (NYSE: QBTS) Trailblazing Efforts in Quantum Market Featured in Bell2Bell Podcast
Lexaria Bioscience Corp. (NASDAQ: LEXX)
The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).
Lexaria Bioscience Corp. (NASDAQ: LEXX) recently provided information to its stakeholders to help them conveniently research and understand different non-affiliated third-party sources and their methodologies for valuing biotech and pharmaceutical companies. The information includes a discussion of underlying logic-based evaluations that offer a realistic framework of expectations that investors can use in their analysis. “One of the logic-based evaluations considers the stage at which a company’s drug development program has reached. According to the U.S. Food and Drug Administration (‘FDA’), there are five steps to the drug development process: discovery and development, preclinical research, clinical research, FDA drug review, and, finally, FDA post-market drug safety monitoring. However, not more than about 250 of 5,000-10,000 compounds tested during the discovery stage successfully transition to the third step. Against this backdrop, Lexaria stands out, having completed the first two steps with its DehydraTECH-CBD for hypertension treatment,” a recent article reads. “A guide prepared by Bay Bridge Bio notes that a company’s valuation increases as its drug development progresses from phase I through phase III… Considering the FDA’s recent confirmation that it agreed with Lexaria’s proposal to pursue a 505(b)(2) new drug application (‘NDA’) regulatory pathway, an abbreviated pathway, the company’s drug development program for hypertension therapeutics could wend way to a multi-billion-dollar valuation in due course.” To view the full article, visit https://cnw.fm/SZI6T
Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.
DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.
Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.
Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.
The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.
DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.
DehydraTECH Technology
Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:
- Speeds up delivery – the effects of the product are felt by the subject in just minutes.
- Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
- Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
- Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
- Reduces drug administration cost – lower doses mean lower overall drug costs.
- Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.
Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.
Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.
Market Outlook
Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:
- Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
- Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
- Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
- Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
- Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
- Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.
Management Team
Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.
John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.
Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.
Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.
Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.
Lexaria Bioscience Corp. (LEXX), closed Thursday's trading session at $2.93, up 1.0345%, on 13,408 volume. The average volume for the last 3 months is 13,408 and the stock's 52-week low/high is $1.85/$7.19.
Recent News
- Lexaria Bioscience Corp. (NASDAQ: LEXX) - CannabisNewsBreaks - Lexaria Bioscience Corp.'s (NASDAQ: LEXX) Hypertension Treatment Program Stands Distinct
- Lexaria Bioscience Corp. (NASDAQ: LEXX) Strengthens Board of Directors to Boost Efforts toward Regulatory Approval of Potential Treatment for Hypertension
- Lexaria Bioscience Corp. (NASDAQ: LEXX) Acquires 27th Worldwide Patent Applying to a Range of APIs in Ready-to-Drink Consumer Retail Beverage Products
Knightscope, Inc. (NASDAQ: KSCP)
The QualityStocks Daily Newsletter would like to spotlight Knightscope, Inc. (NASDAQ: KSCP).
Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, has announced that a locally owned, Oregon-based healthcare system has expanded its contract for its many facilities in the state. The announcement reads, “On the heels of securing a contract for a Knightscope K5 Autonomous Security Robot (‘ASR’), the new client has increased its order for an additional 2 K5 ASRs. The client has a children’s hospital, a 24-hour mental and behavioral health services center, and more than 70 primary care, specialty and urgent care clinics. The hospital’s goal is to deter criminal activity, while enhancing patient and staff experience. Knightscope is proud to play a role in improving the safety of our nation’s healthcare providers, its patients and visitors as it continues its growth in the healthcare vertical.” To view the full press release, visit https://ibn.fm/EwH5
Knightscope, Inc. (NASDAQ: KSCP), founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities targeting to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics, artificial intelligence and electric vehicles.
Knightscope designs and builds Autonomous Security Robots (ASRs) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including multiple Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country.
The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire. You can learn more about the crime fighting wins at www.knightscope.com/crime
The company has achieved several milestones since its creation in 2013, including:
- Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology (Made in the USA)
- Operating for more than 1 million hours in the field and securing contracts across five time zones, from Hawaii to Rhode Island
- Raising over $100 million since inception to build its technology from scratch and generating over $13 million in lifetime revenue, validating both the market opportunity and the technology
Growth Capital & Proposed Nasdaq Listing
With backing from more than 28,000 investors and four major corporations and over $100 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.
On December 1, 2021, Knightscope announced the commencement of an offering of up to $40 million of its Class A common stock, with shares to be listed immediately following closing on the Nasdaq Global Market under the ticker symbol ‘KSCP’. The offering is for up to 4 million shares priced at $10 per share. Learn more at www.knightscope.com/investors
Company Mission – Reimagining Public Safety
Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting the 2+ million law enforcement and security professionals across the country.
Crime has an estimated negative economic impact in excess of $2 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.
Knightscope CEO William Santana Li was interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one-to-one replacement.”
The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.
Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.
Public Safety Innovation
The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings – and significant improvement in capabilities.
Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $3 to $9 per hour, compared with approximately $85 for an armed off-duty law enforcement officer and $15 to $35 for an unarmed security guard.
This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.
Product Offerings
The company has nine patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.
The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’. Learn more at www.knightscope.com/ksoc
The ASRs and the related technologies were developed ground up by the company and are Made in the USA.
The Robot Roadshow
Knightscope has created the ultimate hybrid physical and virtual event, bringing its Autonomous Security Robot technologies to cities across the country for interactive and in-person demonstrations.
Each roadshow landing is hosted virtually by a Knightscope expert, and visitors can interact directly with each of the company’s ASRs and see the Knightscope Security Operations Center (KSOC) user interface in action. Learn more at www.knightscope.com/roadshow
Management Team
Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).
Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.
Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.
Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.
Chief Financial Officer Mallorie Burke is a seasoned financial executive and strategic advisor for both private and publicly traded technology companies with a successful track record of mergers & acquisitions, corporate growth and exit strategies, including public listings.
General Counsel Peter Weinberg leverages 30 years of diverse corporate counsel experience, spanning from startups to well-established companies, private and public. He has significant experience training personnel at all levels in critical areas to improve corporate compliance and productivity.
Knightscope, Inc. (NASDAQ: KSCP), closed Thursday's trading session at $2.87, up 3.6101%, on 361,273 volume. The average volume for the last 3 months is 361,273 and the stock's 52-week low/high is $2.50/$27.50.
Recent News
- Knightscope (NASDAQ: KSCP) - InvestorNewsBreaks - Knightscope Inc. (NASDAQ: KSCP) Secures Expanded Contract with Oregon-Based Client
- InvestorNewsBreaks - Knightscope Inc. (NASDAQ: KSCP) ASR Patrols Portland Hotel, Augments 24/7 Security
- InvestorNewsBreaks - Knightscope Inc. (NASDAQ: KSCP) Robot Roadshow to Take the Spotlight at Underground Atlanta
HeartBeam Inc. (NASDAQ: BEAT)
The QualityStocks Daily Newsletter would like to spotlight HeartBeam Inc. (NASDAQ: BEAT) .
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, today announced issuance of its patent for a 12-lead electrocardiogram (“ECG”) patch monitor intended for detection of acute coronary syndrome (“ACS”) and cardiac arrhythmia by the United States Patent and Trademark Office. According to the update, the innovation builds on HeartBeam’s growing intellectual property portfolio enabling 12-lead ECG diagnostics outside of a medical setting. “This patent provides additional intellectual property protection for our breakthrough ECG patch technology, offering 12-lead ECG capability in the form of a simple patch that is similar in size and shape to existing single-lead ECG patch monitors in the market today,” said HeartBeam CEO and Founder Branislav Vajdic, PhD. “Our 12-lead ECG patch technology offers the potential to bring a level of diagnostic accuracy consistent with the current 12-lead ECG standard of care and could have a disruptive effect on the ECG patch market with its ischemia detection capability.” To view the full press release, visit https://ibn.fm/caCjm
HeartBeam Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector 12-lead electrocardiogram (ECG) platform for heart attack detection anytime, anywhere. The company’s proprietary ECG telehealth technology aims to redefine the way high risk cardiovascular patients are diagnosed in ambulatory and acute care settings. HeartBeam’s initial focus is on providing diagnostic data to help physicians with care management of patients with cardiovascular disease.
In August 2022, HeartBeam announced that it submitted its HeartBeam AIMI™ software for approval from the U.S. Food and Drug Administration (FDA). HeartBeam AIMI is a platform technology to improve the speed and accuracy of heart attack detection in acute care settings. The company expects FDA approval by the end of 2022, and a full commercial roll-out of HeartBeam AIMI is targeted for Q1 2023.
HeartBeam sees submission of its first product based on its platform technology as an important milestone toward commercialization, which underscores the company’s continued progress toward making the HeartBeam AIMI platform widely available to help emergency department physicians quickly and accurately identify a heart attack.
While the FDA conducts its regulatory review, HeartBeam will focus on executing key components of its commercialization plan and subscription revenue model. It will also continue to engage in discussions with strategic institutions, including academic centers, regional healthcare systems and regional community hospital systems that can utilize HeartBeam products.
The company is based in Santa Clara, California.
Products
HeartBeam’s development portfolio includes two products:
- HeartBeam AIMI is software that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack in acute care settings and, as noted above, has been submitted for FDA approval; and
- HeartBeam AIMIGo™, the first and only credit card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system for remote heart attack detection.
HeartBeam is developing AIMIGo, a medical-grade detection and monitoring technology for use in remote heart attack detection, thereby allowing physicians to diagnose a patient’s heart attack as it occurs, even if the patient is not at a medical facility. The company’s system, once approved by the FDA, can be used by patients at home or almost anywhere and anytime to help their physicians assess whether chest pain is the result of a heart attack or another cause. While approximately 82% of chest pain ED visits are unnecessary, patients delay approximately 3 to 4 hours after symptoms begin, increasing mortality rates by 40%. The company’s goal is to shorten the time to treatment outside of the medical facility to improve patients’ well-being.
HeartBeam’s AIMIGo is a powerful, portable and easy-to-use prescription-based product. It comprises a smartphone app, a credit card-sized ECG device placed on a patient’s chest, the HeartBeam cloud platform, and a digital portal for the physician to view ECG results and direct patient action. For the first time outside of a medical setting, HeartBeam AIMIGo enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if needed.
Pending FDA clearance, AIMIGo is initially intended to be available by prescription, and is reimbursable under existing remote patient monitoring codes (RPM codes). This provides a new revenue stream to physicians who before did not have a way to monitor these high-risk patients. The RPM codes provide a monthly reoccurring revenue stream to the company, as well. On average, at current reimbursement rates, the practice will receive $1,300+ per year per patient they monitor, and the company will receive $600 per year per patient from this RPM reimbursement.
Market Overview
Adoption rates of telehealth services increased dramatically in recent years, with the COVID-19 pandemic serving as a major driver of growth. Among the areas seeing the greatest expansion are cardiology, radiology, behavioral health and online consultation.
Encouraging this growth, governments are actively developing new policies and reimbursement guidelines to promote the use of digital health platforms. The U.S. Centers for Medicare & Medicaid Services (CMS), for example, has recently expanded reimbursement for telehealth services. U.S. market growth is also being driven by the rising prevalence of chronic conditions and the growing geriatric population.
Remote heart attack detection is a previously unsolved problem with a massive and underserved market that is several times larger than the $2 billion total addressable market (TAM) in the U.S. for ECG cardiac arrhythmia monitoring.
Approximately 8 million Americans have suffered at least one heart attack, and a total of 18 million have been diagnosed with coronary artery disease (CAD). Based on these figures, HeartBeam projects a total addressable U.S. market TAM valued at $10 billion annually for its AIMIGo solution for remote heart attack monitoring of CAD.
Management Team
Branislav Vajdic, Ph.D., Chief Executive Officer and Founder of HeartBeam, Inc, combines over 30 years of experience in technology development and senior management positions. Dr. Vajdic has been deeply involved with the development of HeartBeam’s technology to fit his vision for the company. Prior to HeartBeam, from 2007 to 2010, Dr. Vajdic was CEO and Founder of NewCardio, a publicly traded company in the cardiovascular devices space. From 1984 to 2007, Dr. Vajdic was at Intel, where he held various senior management position. At Intel, Dr. Vajdic was the designer of first Flash memory and two key inventions that enabled Flash as a product and led engineering groups responsible for Pentium 1 through Pentium 4 designs. Dr. Vajdic was awarded two Intel Achievement Awards, the highest level of award for outstanding contributions to Intel. Dr. Vajdic is author of numerous patents and publications in the fields of cardiovascular devices, as well as chip design. Dr. Vajdic holds a Ph.D. in Electrical Engineering from the University of Minnesota.
Jon Hunt, Ph.D., has over 35 years’ experience in the medical/medical device industry with extensive domestic and international experience in general management, clinical/regulatory, sales and marketing. He also has diverse experience in Fortune 500 companies, as well as start-up environments. Dr. Hunt was the Vice President of Clinical Science and Technology, Medical Device Innovation Consortium, from July 2019 to July 2021, and Vice President of Clinical and Regulatory Affairs, Cryterion Medical from January 2018 to June 2019 (acquired by Boston Scientific Corporation in July 2018 for $202M). Dr. Hunt was the Founding President and CEO of Bardy Diagnostics, Inc. from October 2013 to November 2017 (acquired by Hill-Rom Holdings, Inc.). Prior to joining Bardy Diagnostics, Dr. Hunt spent the previous 11 years as the Vice President of Clinical & Regulatory Affairs with Cameron Health, Inc. (acquired by Boston Scientific Corporation). Dr. Hunt spent the previous 10 years with Cardiac Pacemakers, Inc., St. Jude Medical and Cardiac Pathways Corporation. Dr. Hunt began his career with Cardiac Pacemakers, Inc. (now Boston Scientific Corporation) as the Director of Clinical Programs. He subsequently held positions at St. Jude Medical in Clinical Affairs and as the Business Unit Director for the Cardiac Rhythm Management division for Europe, the Middle East and Africa. At Cardiac Pathways Corporation, Dr. Hunt held various executive positions as Vice President of International Sales and Marketing and Vice President of Worldwide Sales and Marketing (acquired by Boston Scientific Corporation). Dr. Hunt received his Ph.D. in Motor Control from The Pennsylvania State University, his Master’s from California State University, Long Beach and his undergraduate degree from Keele University in the United Kingdom.
Rick Brounstein, HeartBeam’s Chief Financial Officer, combines over 30 years of experience in health technology senior management. Since 2017, Mr. Brounstein has been and is currently a partner of Hardesty, LLC, a financial services firm, and Mr. Brounstein is currently a managing director of CTRLCFO, LLC, a firm Mr. Brounstein founded in 2016 to support funded start-ups in life science and technology. From 2008 to 2011, Mr. Brounstein was Chief Financial Officer of NewCardio, Inc., a microcap public company in the cardiology space, and, over his career, he has been with nine other companies in life science or technology, holding positions including Chief Financial Officer, Chief Operating Officer, Treasurer and Accounting Manager. From June 2001 through November 2007, Mr. Brounstein held several positions at Calypte Biomedical Corporation, a publicly traded medical device company, including Chief Financial Officer and Executive Vice President. In January 2007, Mr. Brounstein was appointed as the National Member Representative for the 2007 COSO Monitoring Project, which published new guidelines for monitoring internal financial controls in February 2009; Mr. Brounstein subsequently was a member of the FEI task force that issued the updated COSO Internal Control Framework in 2013. In March 2005, Mr. Brounstein was appointed to the SEC Advisory Committee on Smaller Public Companies. Mr. Brounstein earned his Certified Public Accountant (CPA) certification while working at Arthur Andersen LLP, formerly a public accounting firm. Mr. Brounstein holds a B.A. in accounting and an M.B.A. in finance, both from Michigan State University.
Ken Persen, HeartBeam’s Chief Technology Officer, combines over 28 years of experience in the medical device and digital health industries in engineering and senior management positions. Mr. Persen has been involved in several companies in Cardiac Rhythm Management, holding positions including Chief Executive Officer, Chief Technology Officer, Executive Vice President and Director of Engineering. Since 2016 and prior to joining HeartBeam, Mr. Persen was the Chief Technology Officer at LIVMOR, Inc., a digital health company. In addition, from 2016 through November 2021, he was also Chief Executive Officer of LIVMOR. Prior roles included Director of Engineering at Cameron Health (acquired by Boston Scientific), a late-stage medical device start up, and engineering and management positions at Guidant Corp. (acquired by Boston Scientific), a large medical device manufacturer. He has an undergraduate degree from University of Minnesota, Duluth, with a BA in Computer Science.
Reklaim Ltd. (NASDAQ: BEAT), closed Thursday's trading session at $2.32, up 85.6%, on 114,305,300 volume. The average volume for the last 3 months is 113.763M and the stock's 52-week low/high is $1.12/$5.4699.
Recent News
- HeartBeam Inc. (NASDAQ: BEAT) - InvestorNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) Secures Additional IP Protection for Breakthrough ECG Patch Technology
- InvestorNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) to Unveil Platform Technology in Virtual Roadshow Webinar
- HeartBeam Announces FDA Submission of HeartBeam AIMI(TM) Product
Freight Technologies Inc. (NASDAQ: FRGT)
The QualityStocks Daily Newsletter would like to spotlight Freight Technologies Inc. (NASDAQ: FRGT).
Freight Technologies (NASDAQ: FRGT), a technology company developing solutions to optimize and automate the supply chain process as well as providing a platform for business-to-business (“B2B”) cross-border shipping in the United States/Mexico/Canada (“USMC”) region, will be presenting today at the H.C. Wainwright 24th Annual Global Investment Conference. Scheduled for Sept. 12–14, the three-day conference has been held in New York City as a hybrid event; participants have been attending both in person and online. Freight Technologies president Mike Flinker and CFO Paul Freudenthaler presented today, and their presentation will be available throughout the day for participants to view. To view the full presentation, visit https://ibn.fm/jHRgQ. To view the full press release, visit https://ibn.fm/Ib5Ia.
Freight Technologies Inc. (NASDAQ: FRGT) (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process, providing a platform for B2B cross-border shipping in the NAFTA region. The company’s mission is to revolutionize cross-border shipping by providing carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road shipping.
Freight Technologies, formerly known as Hudson Capital Inc., assumed its current name and ticker symbol on May 27, 2022. Its primary operating subsidiary and its marketplace are known as Fr8App, and it conducts operations throughout North America under the names of Fr8App and/or Freight App. The company is headquartered in Houston, Texas, with multiple locations across the U.S. and Mexico.
The Fr8Tech Solutions Suite
Fr8Tech leverages artificial intelligence to provide cloud-based platforms aimed at automating the over-the-road transportation process, effectively reducing human touch points and expediting load booking times. The company’s suite of solutions includes:
- Fr8app – A B2B marketplace powered by AI and Machine Learning offering a real-time broker portal to connect shippers with qualified carriers
- Fr8Radar – A tracking solution providing shippers and carriers real-time locational data via Fr8app’s mobile solution or through integration with third-party GPS alternatives
- Fr8TMS – A transportation management system designed to help shippers manage their freight and all of the documents involved in shipping transactions, including invoices, customs documents, confirmation rates and proof of deliveries
- Fr8FMS – A fleet management system allowing transportation companies to better manage their fleets, reduce operational costs and provide better service to their customers
- Fr8Data – A data solution offering real-time dashboards and reports to shippers and carriers in an effort to increase visibility and control while supporting better business decisions
- Fr8Fleet – A platform that provides private fleet management, enabling large corporate shippers to purchase dedicated capacity secured by Fr8app in exchange for a fixed fee
Commitment to the Environment
Through its core focus on technology, Fr8Tech seeks to reduce the carbon footprint of the logistics industry. Its solutions aim to minimize empty miles for transportation firms and reduce overall paper consumption.
Fr8University
Fr8University is an educational program offering classroom and on-the-job training for Fr8Tech team members. Through the program, employees learn in-depth business fundamentals and applications along the truckload freight industry value chain.
Led by corporate educator Mario Mena, Fr8University is designed as an investment in the company’s human capital, providing an opportunity to communicate Fr8Tech’s corporate culture while accelerating operational growth.
Market Outlook
Fr8Tech’s established foothold in Mexico is key to its current efforts to promote sustainable growth in the cross-border shipping industry. Ongoing disruption in U.S.-Chinese trade relations have strengthened Mexico’s status as the largest trading partner of the U.S., with cross-border annual freight spending estimated at $385 billion according to data from the U.S. Department of Transportation. Annual domestic shipping in Mexico is estimated at $34 billion, while annual domestic shipping in the U.S. is estimated to total $732 billion.
Despite the size of this industry, fragmentation and inefficiencies prevail in the space. Thousands of legacy brokers, tens of thousands of shippers and hundreds of thousands of carriers still rely on outdated systems to arrange transport, spending hours on the phone negotiating pricing, waiting days to find trucks and drivers, preparing and printing forms, and operating without tracking or visibility. Add in cross-border complexity relating to customs and additional paperwork, and you have an industry ripe for technological disruption.
Fr8Tech’s recent revenue growth trends have highlighted the company’s efforts to capitalize on this opportunity. In 2021, Fr8Tech achieved revenues of $21.5 million, marking a year-over-year increase of 134%. The company issued revenue guidance for fiscal 2022 of $40 million in a February 9, 2022, press release, which would account for a further 86% year-over-year increase.
Management Team
Javier Selgas is CEO and a Director of Freight Technologies Inc. and Freight App Inc. He brings to the company over 15 years of experience developing technology and digital marketing strategies, including serving as Country Manager for Osigu, Spain, and as head of AJEgroup’s IT division for the Asia-Pacific region. Prior to joining Fr8Tech, Mr. Selgas founded digital marketing agency Lanzadera Online. He has also served as an IT consultant to major corporations, including Endesa and Ibermatica.
Mike Flinker is President of Fr8Tech. He has over four decades of experience in the transportation industry, with 30+ years focused on cross-border logistics. Prior to joining Fr8Tech, Mr. Flinker founded FLS Transportation, the largest cross-border logistics company in Canada. He also previously held positions with Clarke Transport Inc., Canadian Pacific and Reimer Express Inc. (a division of Roadway Express).
Paul Freudenthaler is the company’s CFO and Secretary to the company Board. He has over 30 years of financial expertise, having previously served as CFO for several leading companies across multiple countries, including Macquarie in Mexico, Old Mutual in Latin America and Ascentium Capital in the U.S. Mr. Freudenthaler’s experience include leadership roles from which he guided IPOs and M&A transactions.
Luisa Lopez is COO of Fr8Tech. She brings to the company 25+ years of management experience in logistics, supply chain, operations and customer service. Ms. Lopez previously served as a Director of Landstar, where she was responsible for commercial and client development strategies in the Mexican market. Additionally, she managed more than 2,000 transport units specialized in staff and school mobility while with Traxion in Mexico.
Freight Technologies Inc. (NASDAQ: FRGT), closed Thursday's trading session at $1.01, up 0.989901%, on 110,236 volume. The average volume for the last 3 months is 110,236 and the stock's 52-week low/high is $0.97/$8.734.
Recent News
- Freight Technologies Inc. (NASDAQ: FRGT) - Freight Technologies Inc. (NASDAQ: FRGT) Marks Milestone Intended to Foster Company Growth
- InvestorNewsBreaks - Freight Technologies Inc. (NASDAQ: FRGT) Expands KCM Relationship to Meet Needs for US/Mexico Cross-Border Traffic
- InvestorNewsBreaks - Freight Technologies Inc. (NASDAQ: FRGT) Expands KCM Relationship to Meet Needs for US/Mexico Cross-Border Traffic
Mullen Automotive Inc. (NASDAQ: MULN)
The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).
Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced specifications and unveiled details on the FIVE RS - its ultra-high-performance EV sport crossover. The Mullen FIVE RS will be equipped with 800-volt architecture, all-wheel drive, a two-speed gearbox and over 1,000 horsepower and feature a top speed of 200 mph and acceleration from 0-60 mph in just 1.9 seconds. “From the inception of Mullen, it has been my mission to bring an ultra-high-performance EV to market,” said David Michery, CEO and chairman of Mullen Automotive. “The FIVE RS is intended to be one of the fastest vehicles on the planet, competing with some of the best and most well-known and regarded automotive marquees. I look forward to showcasing this vehicle on the track this next spring.” To view the full press release, visit https://ibn.fm/Ou7ng
Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.
Commencement of Trading on Nasdaq
On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.
“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”
The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.
The Mullen FIVE
The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.
The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.
Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.
LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.
Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.
Expansion of Manufacturing Capacity
On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.
Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.
On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.
EV Market Outlook
The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.
Management Team
David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.
Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.
Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.
Mullen Automotive Inc. (MULN), closed Thursday's trading session at $0.5434, up 2.3159%, on 93,946,292 volume. The average volume for the last 3 months is 93.223M and the stock's 52-week low/high is $0.52/$15.90.
Recent News
- Mullen Automotive Inc. (NASDAQ: MULN) - InvestorNewsBreaks - Mullen Automotive Inc. (NASDAQ: MULN) Provides First Look at Its Ultra-High-Performance FIVE RS
- California Partners with The Netherlands on New EV Charging Technology
- InvestorNewsBreaks - Mullen Automotive Inc. (NASDAQ: MULN) CEO Releases Shareholder Statement in Response Bollinger Motors Majority Acquisition
CNS Pharmaceuticals Inc. (NASDAQ: CNSP)
The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).
Glioblastoma is an aggressive cancer that usually occurs in the spinal cord or the brain. While this cancer can occur at any age, it is more common in adults. The average life expectancy for patients with this type of cancer is between 12 to 15 months. Figures from the Glioblastoma Foundation show that while roughly 14,000 individuals are diagnosed with glioblastomas in America annually, less than 5% survive past the five-year mark. This cancer is usually treated with chemotherapy, surgery and radiation but has a high rate of recurrence, which means the tumors have a higher likelihood of coming back. Three years ago, Rick Miller received a brain cancer diagnosis of glioblastoma. With a fatal illness like this, Miller’s outlook on life did not look rosy. Instead of giving up, Miller signed up for a clinical trial at the University of Maryland’s Medical Center in Baltimore. A lot more efforts are going into developing better ways to treat different brain cancers. For example, CNS Pharmaceuticals Inc. (NASDAQ: CNSP) has a clinical development program in which the company is testing a drug candidate designed to cross the blood-brain barrier and target malignancies afflicting patients. Patients can therefore look forward to a new generation of treatments that deliver better clinical outcomes in the years to come.
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.
The company was founded in 2017 and is headquartered in Houston, Texas.
Organ Targeted Therapeutics
The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.
CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.
CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.
CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.
CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.
The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.
CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.
Global Brain Tumor Therapeutics Market
The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.
A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.
Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.
Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.
One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).
Management Team
John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.
Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.
Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.
Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.
CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Thursday's trading session at $0.246, up 2.5%, on 169,677 volume. The average volume for the last 3 months is 169,677 and the stock's 52-week low/high is $0.20/$1.63.
Recent News
- CNS Pharmaceuticals Inc. (NASDAQ: CNSP) - Focused Ultrasound May Offer Easier Way to Treat Brain Tumors Effectively
- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Takes Aim at Thus-far Incurable GBM Brain Cancer with Human Drug Trials
- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Efforts to Combat GBM Brain Cancer Proceed Amid Competitive Field
Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF)
The QualityStocks Daily Newsletter would like to spotlight Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF) .
- For the quarter that ended June 30, 2022, Reklaim’s year-to-date revenue was up 216% over the same period in the prior year
- During that same quarter, revenue increased 65% over the prior quarter that ended March 31, 2022
- Reklaim grew its B2B customer base by 51% during the quarter that ended June 30, 2022
- The company has 320 million consented consumer profiles
- Reklaim is integrated with 15 of the largest global platforms that sell and distribute data
The company is driven by the evolution of privacy and how it impacts consumers and companies. Reklaim sells compliant, zero-party data to Fortune 500 brands, platforms, and data companies so that they can offset the risk of non-compliance. ‘Zero-party data’ is data that a consumer proactively and intentionally shares with an organization. This contrasts with ‘third-party data,’ which organizations have collected unbeknownst to consumers for more than 20 years. Zero-party data is the most valuable data in the US$200B data market, as it provides organizations with explicit consumer opt-in vs. through an intermediary such as a data broker.
Reklaim empowers consumers to take back control of their data. The company allows consumers to visit the platform, confirm their identity, and uncover their data that has been collected and sold for years without their explicit consent. Consumers can add, edit or delete data that is associated with their profile and choose which pieces of data they would be willing to share for weekly compensation. Reklaim is the only company in the world today providing consumers with both access to their data that is circulating in the market and a guaranteed weekly paycheck. Alternatively, for users who do not want to sell their data, users can choose to protect their data and subscribe to a suite of subscription-based (SaaS) privacy tools that obfuscate the location of their device when browsing on a mobile phone and alert them when a third-party source has leaked their data or passwords.
Reklaim was founded in 2018 and is based in New York, with offices in Toronto.
Business Model
Reklaim’s primary revenue-generating operations stem from selling consented consumer data to companies and resellers that need data that is compliant with all applicable consumer privacy laws and regulations, including the California Consumer Privacy Act (CCPA). Major Fortune 500 customers and enterprise data platforms have validated Reklaim’s zero-party data and have added this data to their marketplaces and decision-making. Reklaim has sales across three core verticals: brands and agencies that buy advertising, platforms that sell data to Fortune 500 clients, and companies whose primary business is selling data to business customers.
- Companies & Agencies that Buy Advertising – These customers use Reklaim’s compliant data to inform their media decisions in social, connected television, programmatic and other verticals. Sales cycles are short at about 30 days. Reklaim customers in this segment are Microsoft, Amgen, Bayer, UPS, and Hasbro, to name a few.
- Platforms that Sell Data – Reklaim has integrated its zero-party data into 15 of the largest enterprise data platforms in the world. These platforms act as the ‘grocery stores’ of data, where the Fortune 500 come to make their data purchases. Reklaim’s data has been validated and added to these platforms, providing ubiquitous distribution of Reklaim data across the data ecosystem. Due to data quality verification and technical requirements, sales cycles are typically longer, about 60-90 days. Customers include LiveRamp, Transunion, Google, The Trade Desk, Lotame, and T-Mobile.
- Data Companies that Sell Data – These customers need to purchase compliant data to continue offering data to their clients. Sales cycles often last 90-120 days, but these contracts are typically annual, have the highest value, and auto-renew. An example is Nielsen, the television measurement company.
Market Outlook
The data industry, valued at $245 billion in the U.S. and more than $400 billion globally, is being disrupted, and Reklaim is positioned to benefit from the destructive shift.
The disruption is driven by two factors: (1) technology is reducing access to core data that the industry has become dependent upon, and (2) government intervention is emerging through laws and regulations intended to protect consumer data privacy.
Over the past 20 years, the data industry has harvested and exploited consumer data without consumers’ express consent. However, the legal and regulatory environment surrounding consumer data acquisition is rapidly evolving, placing the consumer at the center of emerging privacy policies.
The European Union’s General Data Protection Regulation (GDPR) was rolled out in 2019, followed shortly by the CCPA and the California Privacy Rights Act. More recently, the Canadian Privacy Protection Act, Brazil’s General Data Protection Law, India’s Information Technology Act, and South Africa’s Protection of Personal Information have continued the trend. As a result, industries and companies currently relying on unconsented consumer data will experience a regulation-driven disruptive migration, forcing them sooner rather than later to use only fully consented data sources. This consumer data environment is driving companies to Reklaim to replace their current data providers.
While privacy policies continue to iterate to include the consumer, Big Tech, namely Apple and Google, are increasingly removing data from the market that brands and companies have relied on. Apple’s introduction of Advanced Ad Tracing (ATT) has impacted companies’ ability to track consumer behavior across applications. Facebook, in Q4 2021, was forced to accept a US$10B write down on revenue projections due to this change and is expecting a similar US$10B right down again in 2022.
Google is making similar changes, the most significant being the removal of the third-party cookie from its Chrome browser, which has a 65% market share. This third-party cookie is responsible for the tracking that websites use to monetize by tracking consumers. The removal of the Chrome cookie will put the 1.8 billion websites operating in the open web today under pressure to find a solution to replace the 65% loss in revenue.
Management Team
Neil Sweeney is Chairman and CEO of Reklaim. He has more than 20 years in the industry, with an established reputation for visionary entrepreneurship and an ability to develop technologies. Technologies Sweeney created are used by Fortune 500 brands like Coca-Cola, Lowe’s, Walmart, General Motors, Unilever, and Mondelez. They are the core component of top media demand-side platforms, including Adelphic, The Trade Desk, AppNexus, MediaMath, and Triton Media. He is a two-time finalist for Ernst & Young’s ‘Entrepreneur of the Year’ and received Deloitte’s ‘Fast 50’ award for three consecutive years for the growth of organizations he created.
Ira Levy is CFO at Reklaim. He has over 15 years of experience in a wide range of high-growth, early-stage public and private companies. Most recently, he held the roles of Corporate Controller at VIVO Cannabis Inc. (TSX: VIVO) and Senior VP/Head of Finance for start-up Honest Inc. (d/b/a Province Brands of Canada). He has also acted as an advisor for startup AI companies through the Creative Destruction Lab Program. He received his MBA in Accounting and Finance from the Schulich School of Business at York University and is a Chartered Professional Accountant.
Jake Phillips is Chief Technical Officer at Reklaim. He is a proven technology leader who excels at bridging the gap between innovation and business in dynamic environments. He has gained a breadth of industry knowledge across telco/cable, banking, and client services. His professional experience spans enterprise integration, mobility, big data, cloud operations, and data security.
Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF), closed Thursday's trading session at $0.0619, up 0.324149%, on 5,000 volume. The average volume for the last 3 months is 5,000 and the stock's 52-week low/high is $0.04725/$0.3859.
Recent News
- Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF) - Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF) Is 'One to Watch'
- InvestorNewsBreaks - Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF) Plans to Explore Strategic M&A Deals
- Reklaim Announces Appointment of Former CFO as a Director
Silo Pharma Inc. (OTCQB: SILO)
The QualityStocks Daily Newsletter would like to spotlight Silo Pharma Inc. (OTCQB: SILOD).
Silo Pharma (OTCQB: SILOD), a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it will effect a 1-for-50 reverse split of its common stock. Effective at the open of business on Thursday, Sept. 15, 2022, the reverse stock split is in preparation for the planned listing of the company’s securities on the Nasdaq Capital Market (“Nasdaq”). The company’s common stock has begun trading on the OTC Markets system on a split-adjusted basis under the temporary ticker symbol SILOD. The fifth character “D” will remain appended to Silo Pharma’s symbol for 20 business days or until the company is listed on Nasdaq, whichever comes first, at which point the company’s trading symbol will revert back to SILO. The company has filed an application to list its common stock on the Nasdaq and believes it satisfies the financial and liquidity requirements for listing other than the minimum share price rule. The reverse stock split is intended to enable Silo Pharma to meet the stock price requirement for initial listing on the Nasdaq. To view the full press release, visit https://ibn.fm/2QOye
Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry.
Silo is committed to developing innovative solutions to address a variety of underserved conditions. Combining Silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space.
Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves.
Silo recently engaged Donohoe Advisory Associates LLC for consulting and advisory services in connection with the potential uplisting of Silo’s common shares to the Nasdaq Stock Market.
Research
Silo has entered into research agreements and partnerships with multiple leading medical universities.
The company is involved in a sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action. The investigator in the Netherlands is acquiring the substances for the study and will then finalize the documentation to submit to the ethics committee.
Additionally, in June 2021, Silo announced its entry into a scientific research agreement with the University of California San Francisco (UCSF). The agreement will leverage four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation. The study will take place at The Translational Psychedelic Research (TrPR) Program at UCSF.
Silo also recently extended its exclusive option agreement with the University of Maryland, Baltimore (UMB) to explore a novel invention generally known as joint-homing peptides. These peptides are being developed for use in the investigation and treatment of arthritogenic processes and can be used for enhanced targeting of therapeutic agents.
This agreement includes the study of two separate peptides. The first is an option and study for the treatment of arthritis. The second is a patented licensed peptide for the central nervous system, with an initial study for MS autoimmune diseases, in addition to rheumatoid arthritis. Animal studies are underway for both initial indications relating to the UMB agreement, with the potential for studies evaluating additional indications in the future.
Finally, Silo signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD. Both candidates are currently being tested in mice and have already provided early data.
In addition to its university partnerships, Silo entered a joint venture agreement with Zylo Therapeutics Inc. (“ZTI”) focused on the development of ketamine and psilocybin using ZTI’s Z-Pod™ technology for the transdermal time released delivery of therapeutics. In November 2021, the company announced ZTI’s reception of its first ketamine shipment and initiation of loading ketamine into its Z-Pod technology. In a news release, Eric Weisblum, CEO of Silo, called the development an “important milestone” that will help the company “study the benefits of slow-release transdermal release of Ketamine.”
Market Overview
According to Coherent Market Insights, the fibromyalgia treatment market was valued at $2.78 billion in 2018 and has a projected CAGR of 3.3% over the forecast period 2018 to 2026. Fibromyalgia is a condition that causes pain all over the body, sleep problems, fatigue, and emotional and mental distress.
The global PTSD therapeutics market is expected to reach $10.68 billion by 2026 with a CAGR of 4.5% during the forecast period from 2018 to 2026, according to a report by Credence Research. Growing prevalence of PTSD is the chief factor driving the global treatment market. Increases in events such as wars, combat, and interpersonal violence has been a major contributing factor. Other factors like growing emphasis on rehabilitation initiatives by governments for treating their war veterans has also been facilitating the increase in demand for PTSD therapeutics.
Fortune Business Insights reports the global Parkinson’s disease treatment market is predicted to grow to $8.38 billion by 2026, with a CAGR of 8.1% during the forecast period. Parkinson’s is a neurodegenerative disease of the central nervous system which primarily affects the brain, causing uncontrollable shaking and tremors, difficulties in balance and restricted body movement making it difficult for the person to function or perform a daily routine.
Management Team
Eric Weisblum is CEO and founder of Silo Pharma. He has over 25 years of Wall Street experience, most recently in the biotechnology sector. He has served on the board of Aikido Pharma and was the president of Sableridge Capital. He has a proven track record in licensing therapeutic assets and assisting in their development. He brings to the company nearly 20 years of expertise in structuring and trading financial instruments. He holds a bachelor’s degree from the University of Hartford’s Barney School of Business.
Dr. Kevin Muñoz was appointed to the Silo board of directors in October 2020. He teaches biomedical sciences and medical intervention for the Passaic County Technical Institute. He previously served as Director of Operations at Physical Medicine and Rehabilitation. He began his career with Harlem Health Promotion Center in New York City as a research assistant. He earned a bachelor’s degree from the University of Michigan and a Doctor of Medicine from Xavier University School of Medicine.
Josh Woolley, M.D., Ph.D., is a Scientific Advisor for Silo. He is an associate professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco. He is also a psychiatrist on staff at the San Francisco Veterans Affairs Medical Center. He is the director and founder of the Bonding and Attunement in Neuropsychiatric Disorders Laboratory. He received both his M.D. and his Ph.D. in Neuroscience from UCSF, where he completed his psychiatry residency training.
Charles Nemeroff, M.D., Ph.D., is a Scientific Advisor for Silo Pharma. He directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. He was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine. He received his M.D. and Ph.D. in neurobiology from the University of North Carolina School of Medicine.
Silo Pharma Inc. (OTCQB: SILOD), closed Thursday's trading session at $, even for the day. The average volume for the last 3 months is 87,553 and the stock's 52-week low/high is $N/A/$N/A.
Recent News
- Silo Pharma Inc. (OTCQB: SILO) - InvestorNewsBreaks - Silo Pharma Inc. (SILOD) Implements Reverse Stock Split in Preparation for Nasdaq Uplisting
- Study Finds Depression Symptoms in Partners Caring for Dementia Patients May Start Long Before Cognitive Decline
- Georgia Legislators Discuss Psychedelics for Veterans During Committee Hearing
EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF)
The QualityStocks Daily Newsletter would like to spotlight EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF).
EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF), Canada’s renewable natural gas (“RNG”) infrastructure platform, announced an important milestone for the company: its common shares began trading on the OTCQX(R) Best Market in the United States. The shares are trading under the symbol EVGIF, and the uplisting was effective at market open on Sept. 15, 2022. The company had previously traded under the same symbol on the OTCQB(R) Venture Market. According to the announcement, the OTCQX market is an established market that provides qualifying companies with an opportunity to increase visibility, expand liquidity and diversify shareholder base. The exchange is recognized by the United States Securities and Exchange Commission (“SEC”) as an established market. The upgrade in markets gives investors access to EverGen shares through regulated U.S. broker-dealers. “During this milestone-rich quarter for EverGen, we are pleased to provide increased access and liquidity for investors in the U.S. who seek to participate in the energy transition,” said EverGen Infrastructure CEO Chase Edgelow in the press release. “An upgrade to the OTCQX in the United States is a natural progression for EverGen allowing us to introduce our RNG infrastructure platform to a broader audience as we continue to execute on our growth plans with clear visibility to deliver over 1 million gigajoules of RNG annually.” To view the full press releases, visit https://ibn.fm/SJwhA and https://ibn.fm/rWD9j
EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) is developing Canada’s Renewable Natural Gas Infrastructure Platform, starting on the west coast in British Columbia. The company is combating climate change and helping communities contribute to a sustainable future by acquiring, developing, building, owning and operating a portfolio of renewable natural gas (RNG), waste-to-energy, and related infrastructure projects.
While EverGen is currently focused on British Columbia, its continued growth is expected across other regions of North America. RNG is produced differently than conventional natural gas, without drilling wells. RNG is derived from biogas, which is captured from decomposing organic waste in landfills, food waste, agricultural waste matter and wastewater from treatment facilities. This waste feedstock is supplied to an anaerobic digester which contains bacteria that breaks down organic matter in the absence of oxygen. The resulting biogas is captured and cleaned to create carbon neutral or carbon negative RNG to be used by the existing North American gas pipeline grid. By capturing these emissions and transforming them into RNG, then combusting into CO2, the overall greenhouse gases (GHG) impact is materially less potent than allowing natural decomposition to release methane into the atmosphere. Liquid and solid digestate matter is a byproduct of the RNG production process and is used as fertilizer and in other applications.
EverGen operates three projects in British Columbia. The company was incorporated in 2020 and went public in 2021, with its common shares listed on the TSX Venture Exchange under ticker symbol ‘EVGN’. In February 2022, EverGen’s common shares began trading on the OTCQB Venture Market in the U.S. under ticker symbol ‘EVGIF’. The company is headquartered in Vancouver.
Portfolio Projects
Fraser Valley Biogas is one of three projects in EverGen’s portfolio. Located in Abbotsford, British Columbia, the facility has been digesting manure and off-farm organics since 2011 and was the first agricultural digester in Canada to produce RNG. The RNG generated through this project is part of a FortisBC program to supply renewable gas to homes, businesses and other customers. Fraser Valley Biogas also provides Abbotsford farms with renewable fertilizer via the digestate produced. EverGen acquired Fraser Valley Biogas early in 2021 and is currently enhancing and expanding the facility. These optimization projects resulted in record production during the month of September 2021, supporting the growing demand for RNG in British Columbia. Optimization activities contributed an additional 18% of RNG production for September and a 9% higher year-to-date production compared to the previous year. The facility produces approximately 80,000 gigajoules of RNG, enough to heat more than 1,000 homes for a year.
Net Zero Waste Abbotsford, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and RNG expansion project. The British Columbia Utilities Commission recently approved a 20-year offtake agreement between the facility and FortisBC, an electricity and gas utility. Under this agreement, FortisBC will purchase up to 173,000 gigajoules of RNG annually for injection into its natural gas system upon completion of an anaerobic digester project at Net Zero Waste Abbotsford. Once construction is complete, this project is expected to produce enough energy to meet the needs of more than 1,900 homes.
Sea to Sky Soils, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and potential future RNG expansion project which has been operating near Pemberton, British Columbia, on Lil’wat Nation land since 2012. The Lil’wat Nation is a key partner and supporter of the facility, which has employed a majority of its staff from the First Nation since inception. The Sea to Sky Soils facility processed approximately 160 percent of its forecast tonnage in the second half of 2021. In total, Sea to Sky Soils processed approximately 36,000 tons of organic waste in 2021. The facility is working with the Ministry of Environment to expand its operational capacity in 2022. EverGen has partnered with local municipalities – including Metro Vancouver and the municipality of Pemberton – for the delivery of additional organic waste to the facility. The facility is an important part of EverGen’s RNG infrastructure platform and serves as a source of valuable feedstock to support the company’s existing and future operations.
Market Outlook
A report from Global Market Insights states that the biogas market is projected to see significant growth over the next few years, driven by a shifting preference to utilize biogas to reduce emission levels from traditional fuels. Escalating RNG usage by gas utilities as a sustainable and low carbon alternative to supply heat and electricity in industries and buildings will further stimulate growth. RNG is increasingly deployed across the transport sector, especially for heavy vehicles and vessels, to abate GHG emissions.
Many North American gas utilities have set RNG targets of 5% to 15% of production by volume in 2030, compared to less than 1% by volume in 2020. FortisBC has a goal of including 15% RNG in its gas supply by 2030. EverGen believes this presents a potential C$16 billion+ opportunity for RNG producers.
Management Team
Chase Edgelow is co-founder and CEO at EverGen. He has over 15 years of specialized private investment, finance, and technical expertise in the energy and infrastructure sectors. His background is as a Facilities Engineer with Petro-Canada, independently managing energy infrastructure capital projects located in western Canada. He holds a Professional Engineer designation from the province of Alberta.
Mischa Zajtmann is co-founder and President at Evergen. He has 15 years of experience providing consulting and management for Canadian and American companies in the natural resources and energy space. He is a corporate securities lawyer who began his career at Blake, Cassels & Graydon LLP. His J.D. is from the University of Saskatchewan Law School. He’s a member of the British Columbia Bar.
Sean Mezei is COO at EverGen. He has 20 years of experience in the RNG industry, having served previously as the president of Greenlane Biogas and as a senior manager at QuestAir, and founder and president of Dekany Consulting. He was a co-chairman of the American Biogas Council’s RNG working group for six years. He has been a Registered Professional Engineer in the province of British Columbia since 1994.
Natasha Monk is CFO at EverGen. She is a CPA with 12 years accounting, financial reporting, and tax experience in public practice and industry. She is currently a partner at Affirm LLP, where she advises and consults to a wide variety of companies in multiple industries across public and private sectors. Prior to joining EverGen, she worked at KPMG. She graduated from the University of Calgary.
EverGen Infrastructure Corp. (OTCQX: EVGIF), closed Thursday's trading session at $2, even for the day. The average volume for the last 3 months is 2,000 and the stock's 52-week low/high is $2.00/$4.21.
Recent News
- EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF) - InvestorNewsBreaks - EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) Uplists to OTCQX Market Exchange
- InvestorNewsBreaks - EverGen Infrastructure Corp.'s (TSX.V: EVGN) (OTCQB: EVGIF) Upside Potential Featured in Seeking Alpha Article
- GreenEnergyBreaks - EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF) Pioneering RNG Efforts, Growing Footprint
Correlate Infrastructure Partners Inc. (OTCQB: CIPI)
The QualityStocks Daily Newsletter would like to spotlight Correlate Infrastructure Partners Inc. (OTCQB: CIPI).
- Correlate Infrastructure Partners Inc. is a Louisiana-based developer of energy use solutions that is focused on providing data-driven energy analysis and advisement to commercial real estate developers
- Correlate recently announced that it is partnering with Ultra Yield Solutions (“UYS”) to improve energy use services to indoor horticultural growers
- The indoor horticultural industry, also known as controlled environment agriculture or CEA, is rising in popularity thanks to consumer efforts to promote locally grown produce year-round
- Under the partnership, UYS will take care of clients’ professional indoor farming LED design needs while Correlate will handle the solar, storage, and funding solutions
Indoor horticulture, also known as controlled environment agriculture or CEA, is increasing in popularity as consumer demand for produce grown closer to home under year-round, clean-control conditions continues to rise. The market sustaining CEA produce is predicted to increase at a CAGR of 10.9 percent from 2021 to 2028, according to Research and Markets analysts cited in an AgriTech Tomorrow report earlier this year (https://ibn.fm/ri7kc). As the demand for indoor-grown produce increases, the need for energy-efficient CEA-friendly lighting is also on the rise according to the AgriTech Tomorrow report, highlighting efforts to power what for many is becoming a passion project. Correlate Infrastructure Partners (OTCQB: CIPI), a company focused on reducing climate change through improving the ways commercial buildings use energy, announced recently that it is entering the CEA space thanks to a partnership the company inked with horticulture lighting distributor Ultra Yield Solutions (“UYS”).
Correlate Infrastructure Partners Inc. (OTCQB: CIPI), formerly Triccar Inc., through its two subsidiaries, Correlate and Solar Site Design, offers a complete suite of proprietary clean energy assessment and fulfilment solutions for the commercial real estate industry. The company believes scaling distributed clean energy solutions is critical in mitigating the effects of climate change. CIPI is at the forefront in creating an industry-leading energy solution and financing platform for the commercial and industrial sector. The company sees tremendous market opportunity in reducing site-specific energy consumption and deploying clean energy generation and energy efficiency solutions at scale.
The opportunity exists to remove friction between today’s legacy finance process and the needed clean-energy upgrades developed within the company’s program technologies. For the U.S. to reach its 2050 carbon goals, 200,000 commercial buildings must be retrofitted every year until that date. That represents approximately a 5-10x increase over the 2022 industry process run rate.
CIPI announced completion of its acquisition of 100% of the equity of Correlate Inc. and Loyal Enterprises LLC dba Solar Site Design on December 28, 2021. The company notes these acquisitions occurred at a key inflection point of its growth. CIPI currently enjoys channel and sales partnerships with Fortune 250 companies and a strong, proven industry network.
The company’s transparent, leading-edge model changes value delivery for both facility owners and proven solution providers seeking scale. CIPI believes its rapid growth is due to industry demand for actionable, cashflow positive energy programs and the underlying carbon reduction mandates taking effect globally.
CIPI has filed with the SEC for a name change to Correlate Infrastructure Partners Inc., which will more closely reflect its new platform and growth focus. The company has been aggressively moving to rebrand, with efforts including a revised website, investor presentation materials and an investor relations awareness campaign. The company’s shares will continue to trade on the OTCQB Venture Market under the current ‘CIPI’ ticker symbol until changes are approved.
Subsidiaries
Correlate, founded in 2015, is a portfolio-scale development and finance platform offering commercial and industrial facilities access to clean electrification solutions focused on locally-sited solar, energy storage, EV infrastructure, and intelligent efficiency measures. Its unique data-driven approach is powered by proprietary analytics, concierge subscription services, and a highly scalable national fulfillment network to help building owners profit from fully funded, turnkey decarbonization and facility health programs. The platform is designed for commercial and industrial real estate owners seeking to significantly improve net operating income while meeting carbon reduction goals. The platform provides energy programs for commercial property portfolios and requires no upfront capital. Client organizations reduce their risk and generate more profits by leveraging Correlate’s unique payment programs to put more cash in the bank. Deploying Correlate’s strategic energy programs and energy management systems allows property-owning organizations to complete big energy changes across their portfolios.
Solar Site Design, founded in 2013, is a U.S. Department of Energy Sunshot Catalyst winner that provides customer acquisition and project development tools for the commercial solar industry. Its commercial marketplace platform connects highly qualified project opportunities to leading solar construction companies nationwide. The Solar Site Design platform gives commercial and industrial property owners access to the best price for a commercial solar system. Commercial solar analysts provide property owners a site assessment and working project proposal. Solar Site Design’s team of solar engineers finalize the design while approved financing providers help clients explore financing options for their projects. Then, approved contractors in Solar Site Design’s Marketplace bid on the projects, ensuring commercial and industrial property owners get the best estimates for their projects. Solar Site Design’s marketplace process promotes transparency and fair pricing. Its team of experts has nearly 20 years of experience in the solar industry. Only reputable, experienced, certified (NABCEP), licensed, bonded and insured contractors are accepted into the Solar Site Design Marketplace.
Market Outlook
CIPI is in a rapidly growing market with a unique offering to address a total market of more than 5.9 million commercial buildings in the United States, according to the U.S. Energy Information Administration. Currently, the company’s wholly owned subsidiaries, Correlate and the Solar Site Design, have an opportunity pipeline of over $100 million in commercial projects with more than $20 million in awarded backlog. According to the Rocky Mountain Institute, portfolio energy optimization is a $290 billion market in the United States driving deep financial savings and energy efficiency across the commercial sector.
Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon, and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed.
In today’s real estate market, portfolio property owners own most commercial buildings. Yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which has very different needs than traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. CIPI’s financial instruments and software breakdown this issue known as the “split incentive”, unlocking the majority of the addressable market.
Management Team
CIPI has in place a nationally recognized management team that has been active in the energy market since 2005.
Todd Michaels is President and CEO of CIPI and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems.
Channing Chen is CFO at CIPI and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space.
David Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky.
Jason Loyet is VP of Commercial Sales of Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA).
Deke Welling is Head of Project Development and Fulfillment Services at Correlate Inc. He has over 19 years’ experience in the energy industry with an emphasis on renewables and energy efficiency over the past seven years. Prior to entering the renewables sector, Mr. Welling was the CEO of Welling Resources, an energy development company focused on the exploration of oil and natural gas reserves in the U.S. It was this experience that led him into the renewables sector and leading a charge for more sustainable resources. Additionally, Mr. Welling also served as the CEO of Circle L Solar Inc., a top 100 solar installer in the United States since 2016. Through his leadership, Circle L Solar experienced a growth rate of over 2,250% from 2016 to 2019, resulting in his company being listed on the Inc. 5000 list of the fastest growing private companies in the U.S. (Rank #176) and being named ‘Top Energy Company’ and ‘Entrepreneur of Year for the Energy Industry’ by the American Business Awards® in 2019 and again for ‘Entrepreneur of the Year’ in 2021.
Kevin Warren is Head of Construction and Development Engineering at Correlate Inc. He is a solar veteran with over 12 years of experience in the field. Prior to co-founding CLS, Mr. Warren was the owner of Beacon Consulting and has originated, consulted, designed and/or engineered over 122 MW of PV installations ranging from small commercial to utility scale projects throughout Texas, California, Colorado and North Carolina. He holds a Photovoltaic Technical Sales Professional Certification from the North American Board of Certified Energy Practitioners and certifications from Solar Energy International in PV Installation, PV Technical Sales, PV battery-based design, PV design and engineering, and PV operations and maintenance. Along with PV expertise, Mr. Warren is a LEED Green Building Associate, a certified building analyst from the Building Performance Institute, a Certified Renewable Energy Professional from the Association of Energy Engineers and holds a designation in High-Performance Sustainable Buildings from the BOMI Institute. He studied Electrical Engineering at the University of Texas at Arlington.
Tom Kunhardt is Director of Customer Success at Correlate. He previously held a similar position at Clean.Tech and was Corporate Trainer, Learning & Development, at NRG Energy. He has 15 years of experience in the solar and clean energy industries helping homeowners and businesses find solutions to their energy needs. He holds a bachelor’s degree from the University of Massachusetts.
Correlate Infrastructure Partners Inc. (OTCQB: CIPI), closed Thursday's trading session at $1.55, even for the day. The average volume for the last 3 months is 2,100 and the stock's 52-week low/high is $0.32/$3.25.
Recent News
- Correlate Infrastructure Partners Inc. (OTCQB: CIPI) - Correlate Infrastructure Partners Inc. (CIPI) Teams with CEA Lighting Distributor UYS to Boost Indoor Horticulture Services
- Correlate Infrastructure Partners Inc. (CIPI) Helping Organizations Achieve their ESG Goals with its ESG-Related Energy Solutions
- InvestorNewsBreaks - Correlate Infrastructure Partners Inc. (CIPI) Moves to Complete Key Acquisition, Bring Proven Success into Northeast Renewables Market
Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F)
The QualityStocks Daily Newsletter would like to spotlight Hillcrest Energy Technologies Ltd. (OTCQB: HLRTF).
Hillcrest (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA), a clean technology company, addresses the design and mechanical challenges faced by manufacturers in the EV space, which are brought by inverter size and power density. The company’s conversion technologies and control systems solutions reduce the size and weight of inverter designs with the potential to disrupt the electrification industry. “Enabling switching at higher frequencies with Hillcrest’s Zero Voltage Switching (‘ZVS’) inverter technology can result in a significant increase in power density, partly due to the reduction in the size of capacitors needed and in turn reducing the overall size, weight and cost of an inverter. Hillcrest’s technology allows for lighter high-efficiency power inverter solutions that reduce overall weight, increase payload, decrease heat production, and boost the vehicle’s range capability,” a recent article reads. “Capacitance for a typical EV traction inverter today is between 600 microfarads and 1 millifarad, while the commercial prototype design of the Hillcrest traction inverter contemplates one-fifth to one-tenth of the capacitance… Such a significant reduction in capacitor and inverter size and increase in power density, coupled with improved power quality and system reliability, has the potential to disrupt power inverter designs across the automotive space,” Hillcrest CTO Ari Berger is quoted as saying. To view the full article, visit https://ibn.fm/4rMdL
Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F) is a clean technology company based in Vancouver, British Columbia, engaged in developing high-value, high-performance power conversion technologies and digital control systems for next-generation powertrains and grid-connected renewable energy systems.
From concept to commercialization, Hillcrest invests in the development of energy solutions that power a more sustainable and electrified future. Hillcrest power inverter technology helps produce efficiencies in electrification and maximize the performance of electric systems, including electric vehicles (EV), motors and generators.
The company offers a flexible, single-inverter architecture that can be applied at nearly every stage of the electrification ecosystem, from renewable energy generation through the charging and operation of an EV, to provide full-cycle efficiency and performance improvements.
As momentum to electrify and decarbonize energy systems accelerates, Hillcrest believes the power inverter is increasingly emerging as a key component. While system cohorts such as battery packs, PV panels and electric motors are often in the spotlight, the inverter holds the key to unlocking efficiency and performance improvements.
Hillcrest power inverter technology is:
- REVOLUTIONARY: high-efficiency inverter technology has the potential to revolutionize how motors respond and how efficiency is gained.
- AGILE: able to deliver and deploy high-efficiency inverter solutions purpose-designed to meet specific customer needs.
- INNOVATIVE: technology-forward, clean-energy experts who are focused on advancing and optimizing efficient alternative energy use across all electric vehicle and charging platforms.
- A MARKET LEADER: a next-generation technology provider to the automotive industry’s top suppliers and manufacturers.
Technology & Applications
Hillcrest’s first application for its inverter technology – a 250 kW|800V Hillcrest SiC high efficiency traction inverter – is focused on the growing EV market. Hillcrest technology eliminates traditional design trade-offs faced across the power industry – deploying higher switching frequencies has historically meant a greater increase in losses, lower system efficiency and higher heat. Through a combination of hardware and software expertise, Hillcrest enables power applications to leverage higher switching frequencies AND
- Realize improved power system performance and reliability
- Operate at higher power levels without compromising efficiency
The expected benefits of Hillcrest’s traction inverter have been confirmed via testing and shared in a technical white paper, published in April 2022, that confirmed the following results:
- Significant efficiency gains – 99%-plus inverter efficiency
- Increased power density targeting 50kW/L+
- Significantly increased motor efficiency
- Lower stress on mechanical and electrical parts, enhancing reliability
- Improved thermal management
Hillcrest has also filed a patent for an enhanced powertrain solution that offers the potential to simplify EV charging and redefine how the industry envisions charging infrastructure. The company believes the most exciting benefit of the enhanced powertrain solution is the ability to eliminate the onboard charger and booster from an EV, as well as faster, anywhere charging including direct DC, wireless, and bidirectional charging across current and future power levels. Hillcrest sees this as a true EV charging game changer.
The company’s technology applies to nearly every clean energy industry segment:
- Wind power – an inverter is deployed at a wind turbine generator to convert the AC output, with at least one additional inverter used to deliver the power to the grid/battery.
- Solar power – an inverter is used to convert the DC output from the photovoltaic panels into the AC power that flows to the grid/battery/home.
- Energy storage – an inverter is deployed to convert the DC output from the storage system or batteries to the AC power that flows to the grid/home/EV.
- EV fast chargers – an inverter converts the AC input from the grid/storage system to the DC output needed to charge an EV’s battery.
Market Outlook
According to an April 2022 market analysis by Vantage Market Research (VMR), the global power inverter market is expected to reach a value of $95 billion by 2028, driven by increasing demand for EVs, energy generating wind turbines and solar-powered photovoltaic systems. That jump is forecast from an estimated $70.5 billion market value in 2021 and represents a compound annual growth rate of more than 5%.
According to the VMR report, many governments in countries around the world are supporting alternative options for efficient and nonpolluting energy generation. This has boosted demand for wind energy and solar energy systems. Hillcrest is aiming to capture a share of this future market growth across nearly every segment of the clean energy industry.
Management Team
Don Currie is the founding CEO of Hillcrest Energy Technologies. He has led the company’s successful transition from fossil fuels into clean energy technologies. Earlier in his career, he held various senior level positions, including director, officer and vice president of corporate communications with Enhanced Oil Resources Inc., an oil and gas exploration and production company based in Houston. Prior to that, he worked in other private and public ventures spanning the mining, gaming and technology sectors.
Jamie L. Hogue is the COO of Hillcrest. She brings more than two decades of progressive policy leadership, economic analysis and organizational development experience to Hillcrest. She builds collaborative processes and solutions that drive growing organizations toward a more resilient future. She previously served as the director of operations for Arizona State University’s Ten Across initiative – a compelling observatory positioned on the front lines of economic, social and climate change. She earned a master’s degree in public administration and a bachelor’s degree in economics from Arizona State University.
Ari Berger is Chief Technology Officer at Hillcrest. He brings over a decade of commercial experience with a track record of deploying new electrification technologies and go-to-market strategies. In 2015, he founded NIG Systems Ltd. in Israel, which specializes in custom high performance control systems design. Prior to this, he previously worked for Bental Industries, a leading motor manufacturer. He holds a master’s degree in system control engineering from the Technion – Israel Institute of Technology.
Raj Clair is CFO at Hillcrest. She is a CPA who began her career at Deloitte and has served in advanced finance positions in the energy and resources sector. She has been responsible for reporting, audits and internal controls, as well as working on budgeting and forecasting. She has worked with various publicly listed companies, including SEC registrants, and has both Canadian and U.S. experience. She holds a bachelor’s degree in accounting from Simon Fraser University.
Hillcrest Energy Technologies Ltd. (NASDAQ: HLRTF), closed Thursday's trading session at $0.094, even for the day. The average volume for the last 3 months is 24,390 and the stock's 52-week low/high is $0.075/$0.1826.
Recent News
- Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F) - Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA) at the Wheel as EV Evolution Shifts into Next Gear
- InvestorNewsBreaks - Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F) Called 'Potential Breakthrough' by New Research Report, Earns Buy-Venture Rating
- Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA) Demonstrates Disruptive Potential of its Electrification Technology
The QualityStocks Numbers Report
The QualityStocks Sponsored News
- 180 Life Sciences Corp. (NASDAQ: ATNF) - InvestorNewsBreaks - 180 Life Sciences Corp. (NASDAQ: ATNF) Enrolls First Patient in Early-Stage Frozen Shoulder Trial
- Aditxt Inc. (NASDAQ: ADTX) - Aditxt, Inc. (Nasdaq: ADTX) Announces 1-for-50 Reverse Stock Split Effective Pre-Market Opening on September 14, 2022
- Advanced Container Technologies Inc. (OTC: ACTX) - 420 with CNW - King's College London Plans Largest Study on Marijuana
- American Cannabis Partners - 420 with CNW — California Cannabis Authority Enters Partnership with CPPC
- Amesite Inc. (NASDAQ: AMST) - InvestorNewsBreaks - Amesite Inc. (NASDAQ: AMST), NAFEO Welcome New Members to Alliance Designed to Offer Online Learning Opportunities
- AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) - AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Appeal
- AmpliTech Group Inc. (NASDAQ: AMPG) - InvestorNewsBreaks - AmpliTech Group Inc. (NASDAQ: AMPG) Releases Acquisition Update, Anticipated Results
- AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) - SUSTAINN, AREV's Ready to Use Therapeutic Foods discussed in leading article in HealthHIV
- Augmedix Inc. (NASDAQ: AUGX) - Augmedix to Participate at the 2022 Lytham Partners Fall Investor Conference
- Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) - InvestorNewsBreaks - Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Releases Q2 2022 Report
- BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) - InvestorNewsBreaks - BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) Releases Shareholder Update with Corporate, Operational Highlights
- Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) - InvestorNewsBreaks - Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) Announces Joint Agreement, Expanded Opportunity in Overseas Gaming Market
- Brain Scientific Inc. (OTCQB: BRSF) - InvestorNewsBreaks - Brain Scientific Inc. (BRSF) Secures CE Mark Approval for NeuroCap(TM)
- Cannabis Strategic Ventures Inc. (OTC: NUGS) - 420 with CNW - White House Reveals President Biden Has No Plans to Act on Cannabis Reform Ahead of Midterms
- Cerberus Cyber Sentinel Corp. (NASDAQ: CISO) - InvestorNewsBreaks - Cerberus Cyber Sentinel Corp. (NASDAQ: CISO) Appoints Seasoned Veteran as M&A Legal Counsel
- CNS Pharmaceuticals Inc. (NASDAQ: CNSP) - Focused Ultrasound May Offer Easier Way to Treat Brain Tumors Effectively
- Correlate Infrastructure Partners Inc. (OTCQB: CIPI) - Correlate Infrastructure Partners Inc. (CIPI) Teams with CEA Lighting Distributor UYS to Boost Indoor Horticulture Services
- Cub Crafters Inc. - CubCrafters Inc.’s Popularity is Displayed by Quick Response to its Pending Public Offering, while the Backcountry Aircraft Manufacturer Awaits SEC Qualification
- Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) - Study Suggests Reported Psychedelics Microdosing Effects Are Due to User Expectancy
- DarioHealth Corp. (NASDAQ: DRIO) - InvestorNewsBreaks - DarioHealth Corp. (NASDAQ: DRIO) Releases Q2 2022 Financial Report, Corporate Update
- DealMaker - InvestorNewsBreaks – DealMaker CEO Featured on ‘Gamechangers LIVE’
- D-Wave Quantum Inc. (NYSE: QBTS) - D-Wave Demonstrates Large-Scale Coherent Quantum Annealing
- Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) - Congressman Says Lawmakers' Reluctance Regarding Psychedelic Therapy Is Embarrassing
- DSG Global Inc. (OTCQB: DSGT) - InvestorNewsBreaks - DSG Global Inc. (DSGT) Secures ICON Capital Group as Financial Advisor to Pursue Strategic Spinout
- Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF) - Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF) Welcomes Plant-based Industry Pioneer and former Director of Beyond Meat to Advisory Board Amid Ramp-up of Healthful Food Innovations, Distribution
- Strong Earnings, Revenue Reports from Plant-based Foods Maker Belle Pulses, Drives Cheery Assessment for Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF)
- ESGBreaks - Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF) Lays Strong Foundation in 'Seed-to-Market' Approach
- Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) - Power Conversion Innovation May Boost Power Plant Efficiency
- Exro Technologies Inc. (TSX: EXRO) (OTCQB: EXROF) - Exro Announces Closing of Brokered Public Offering and Update on Concurrent Non-Brokered Private Placement
- FingerMotion Inc. (NASDAQ: FNGR) - FingerMotion Inc. (NASDAQ: FNGR) Upgrades to Sapientus Analytics Division Hone in on Tech Tool Trends in China
- First Energy Metals Ltd. (CSE: FE) (OTCQB: FEMFF) - InvestorNewsBreaks - First Energy Metals Ltd. (CSE: FE) (OTCQB: FEMFF) (WKN: A2JC89) Options Two Lithium Claims Directly Adjacent to 'Electric Avenue'
- Flora Growth Corp. (NASDAQ: FLGC) - 420 with CNW - Four Novel Ways in Which Hemp Can Be Used Today
- Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX) - InvestorNewsBreaks - Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX) Investor Conference Presentation Available on Company Website
- Freight Technologies Inc. (NASDAQ: FRGT) - Freight Technologies Inc. (NASDAQ: FRGT) Marks Milestone Intended to Foster Company Growth
- Friendable Inc. (FDBL) - As Congress Looks to Change How Streaming Services Pay Musicians, Friendable Inc. (FDBL) Offers Viable Solution with 360-Degree Platform Supporting Music Artist Production, Distribution, and Marketing
- FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) - InvestorNewsBreaks - FuelPositive Corporation (TSX.V: NHHH) (OTCQB: NHHHF) to Present at H.C. Wainwright 24th Global Investment Conference
- GeoSolar Technologies Inc. - GeoSolar Technologies Inc. Offers Potentially Ground-Breaking Solution as the World Goes Through Arguably Most Important Transition Ever
- Golden Matrix Group Inc. (NASDAQ: GMGI) - InvestorNewsBreaks - Golden Matrix Group Inc. (NASDAQ: GMGI) Achieves Record Revenues, 16th Consecutive Quarter of Profitability
- Golden Triangle Ventures Inc. (OTC: GTVH) - InvestorNewsBreaks - Golden Triangle Ventures Inc. (GTVH) Appoints New Global Health Services CEO
- Genprex Inc. (NASDAQ: GNPX) - InvestorNewsBreaks - Genprex Inc. (NASDAQ: GNPX) CFO to Present Pioneering Gene Therapies at Upcoming Conference
- Green Hygienics Holdings Inc. (OTCQB: GRYN) - InvestorNewsBreaks - Green Hygienics Holdings Inc. (GRYN) Enters US Plant-Based Food Market with Superior Hemp Protein Product
- GreenBox POS (NASDAQ: GBOX) - InvestorNewsBreaks - GreenBox POS (NASDAQ: GBOX) to Present at 24th Annual H.C. Wainwright Global Investment Conference
- HeartBeam Inc. (NASDAQ: BEAT) - InvestorNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) Secures Additional IP Protection for Breakthrough ECG Patch Technology
- Cepton Inc. (NASDAQ: CPTN) - Cepton, Inc. (NASDAQ: CPTN) - Experts Confirm Lidar Technology Provides Superior Automotive Safety Compared to Camera-only Systems
- Hemptown USA - InvestorNewsBreaks - Hero Technologies Inc. (HENC) Common Stock Upgraded to Mid-Tier OTC Equity Market
- Hero Technologies Inc. (OTC: HENC) - InvestorNewsBreaks - Hero Technologies (HENC) Looking to Acquire Land to Serve as Basis for Growing Cannabis Business
- Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F) - Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA) at the Wheel as EV Evolution Shifts into Next Gear
- Home Bistro Inc. (OTC: HBIS) - InvestorNewsBreaks - Home Bistro Inc. (HBIS) Announces Q3 2022 Financial Results
- iClick Interactive Asia Group Ltd. (NASDAQ: ICLK) - InvestorNewsBreaks - iClick Interactive Asia Group Limited (NASDAQ: ICLK) Announces Q2 2022 Unaudited Financial Results
- Ideanomics Inc. (NASDAQ: IDEX) - InvestorNewsBreaks - Ideanomics Inc. (NASDAQ: IDEX), ABC Companies Partner to Expand Distribution of Exclusive WAVE Wireless Charging Solutions
- Infobird Co., Ltd (NASDAQ: IFBD) - InvestorNewsBreaks - Infobird Co. Ltd. (NASDAQ: IFBD) Partners with Global Multinational Enterprise for 'Customer Win' and Food-Service Distribution Milestone
- InMed Pharmaceuticals Inc. (NASDAQ: INM) - InvestorNewsBreaks - InMed Pharmaceuticals Inc. (NASDAQ: INM) Closes $6M Private Placement Agreement
- InnerScope Hearing Technologies Inc. (OTC: INND) - InvestorNewsBreaks - InnerScope Hearing Technologies Inc. (INND) Announces Completion of 2019, 2020 Audited Financial Statements
- Innovative Payment Solutions Inc. (OTCQB: IPSI) - Innovative Payment Solutions, Inc. Appoints Richard Rosenblum as President and Chief Financial Officer
- BlockQuarry Corp. (OTC: BLQC) - Interoperability Crucial to Mass Adoption of Blockchain Technology
- Knightscope (NASDAQ: KSCP) - InvestorNewsBreaks - Knightscope Inc. (NASDAQ: KSCP) Secures Expanded Contract with Oregon-Based Client
- Kronos Advanced Technologies Inc. (OTC: KNOS) - InvestorNewsBreaks - Kronos Advanced Technologies Inc. (KNOS) Positioned Amid Expected Growth of Indoor Air Quality Market
- Laredo Oil Inc. (OTC: LRDC) - ESGBreaks - Laredo Oil Inc. (LRDC) Ideally Poised as Bullish 2023 Forecast Suggests Pricing Uptrend
- Lexaria Bioscience Corp. (NASDAQ: LEXX) - CannabisNewsBreaks - Lexaria Bioscience Corp.'s (NASDAQ: LEXX) Hypertension Treatment Program Stands Distinct
- Lottery.com Inc. (NASDAQ: LTRY) - InvestorNewsBreaks - Lottery.com (NASDAQ: LTRY) Releases Q1 Financial, Operational Results
- LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) - CryptoNewsBreaks - LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) at Forefront to Implement Cryptocurrency as Viable Monetary Solution
- LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) Leverages Over 30 BTC Capacity and 300 Channels Across 17 Countries on Lightning Network
- CryptoNewsBreaks - LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) Eyes Lightning Growth with >56K Transactions and Counting
- MedSmart Group Inc. (OTC: MSGP) - InvestorNewsBreaks - MedSmart Group Inc. (MSGP) Announces Milanion Limited's Inroads into Ukraine Through Strategic MOU
- Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) - MINDCURE Announces Financial Results for Fiscal 2022
- Mobius Interactive Ltd. - InvestorNewsBreaks – Mobius Interactive Ltd.’s Mobius.bet Poised in Lucrative Emerging Market
- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) - InvestorNewsBreaks - Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Files Prospectus Supplement, Closes First Tranche Under Subscription Agreement
- Nemaura Medical Inc. (NASDAQ: NMRD) - InvestorNewsBreaks - Nemaura Medical Inc. (NASDAQ: NMRD) Announces Participation at Upcoming H.C. Wainwright Global Investment Conference
- Mullen Automotive Inc. (NASDAQ: MULN) - InvestorNewsBreaks - Mullen Automotive Inc. (NASDAQ: MULN) Provides First Look at Its Ultra-High-Performance FIVE RS
- Nexstar Media Group Inc. (NASDAQ: NXST) - InvestorNewsBreaks - Nexstar Media Group Inc. (NASDAQ: NXST) Announces 17th Market to Launch ATSC 3.0 This Year
- Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF) - InvestorNewsBreaks - Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF) (FSE: N29) Appoints New CEO to Take 'Map D' to next Level of Growth
- Nowigence Inc. (OTCQB: NOWG) - Nowigence Inc. (NOWG) Starts Trading on OTC
- Odyssey Group International Inc. (OTC: ODYY) - Odyssey Health, Inc.'s (ODYY) PRV-002 Drug Candidate Designed to Immediately Mitigate the Effects of Concussion on Brain Function
- PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) - InvestorNewsBreaks - PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) Announces Distribution Agreement to Expand Little West Cold Pressed Juices Footprint
- Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF) - InvestorNewsBreaks - Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF) (FSE: 7CR) Inks Licensing, Distribution Agreement with Global iGaming Aggregator
- PowerTap Hydrogen Capital Corp. (NEO: MOVE) (FWB: 2K6A) (OTC: MOTNF) - InvestorNewsBreaks - PowerTap Hydrogen Capital Corp. (NEO: MOVE) (OTC: MOTNF) (FWB: 2K6) Engages T2M for Rapid Deployment of Gen3 Hydrogen Unit
- Predictive Oncology (NASDAQ: POAI) - InvestorNewsBreaks - Predictive Oncology Inc. (NASDAQ: POAI) Releases Q2 Financial Report
- Pressure BioSciences Inc. (PBIO) - InvestorNewsBreaks - Pressure BioSciences Inc. (PBIO) Announces Participation at H. C. Wainwright Annual Global Investment Conference
- Prime Harvest Inc. - 420 with CNW — Director of Federal Health Agency Blasts Cannabis Research Barriers Impeding Opioid Research
- Processa Pharmaceuticals Inc. (NASDAQ: PCSA) - InvestorNewsBreaks - Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Shares Update on Clinical Programs Enrollment
- QSAM Biosciences Inc. (OTCQB: QSAM) - Researchers Find Cases of Osteosarcoma More Prevalent in Blacks
- Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) - Top Marijuana Penny Stocks Right Now? 3 For Your List In September
- Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF) - Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF) Is 'One to Watch'
- REZYFi, Inc. - InvestorNewsBreaks – REZYFi Inc. Engages IBN for Corporate Communications Expertise
- RYAH Group Inc. (CSE: RYAH) - InvestorNewsBreaks – RYAH Group Inc. (CSE: RYAH) Announces Industry Veteran as New VP Overseeing IP Commercialization
- Sanwire Corp. (SNWR) - InvestorNewsBreaks - Sanwire Corporation (SNWR) Subsidiary Releases Q2 Financial Results, Corporate Update
- Save Foods Inc. (NASDAQ: SVFD) - InvestorNewsBreaks - Save Foods Inc. (NASDAQ: SVFD) Sees New Customer Growth as Mexican Lime Producers Adopt Protection Treatment
- Sharing Services Global Corporation (SHRG) - InvestorNewsBreaks - Sharing Services Global Corporation (SHRG) Announces Official Launch Event for Hapi Travel
- Sigma Additive Solutions (NASDAQ: SASI) - InvestorNewsBreaks - Sigma Additive Solutions (NASDAQ: SASI) Announces Q2 2022 Financial Results
- Silo Pharma Inc. (OTCQB: SILO) - InvestorNewsBreaks - Silo Pharma Inc. (SILOD) Implements Reverse Stock Split in Preparation for Nasdaq Uplisting
- Siyata Mobile Inc. (NASDAQ: SYTA) (TSXV: SIM) - InvestorNewsBreaks - Siyata Mobile Inc. (NASDAQ: SYTA) Integrates SD7 with CrisisGo Panic App to Improve Crisis Communication Between Teachers, First Responders
- Simply Sonoma Inc. - InvestorNewsBreaks – Simply Sonoma Enters Growing CBD-Infused Beverages Space
- Splash Beverage Group Inc. (NYSE American: SBEV) - InvestorNewsBreaks - Splash Beverage Group Inc. (NYSE American: SBEV) Finalizes Distribution Agreements in Nevada, Maryland for SALT Tequila Brand
- SPYR Inc. (OTCQB: SPYR) - InvestorNewsBreaks - SPYR Inc. (SPYR) Subsidiary Patented Platform Provides Smart Solutions for Simple IoT Problems
- SRAX Inc. (NASDAQ: SRAX) - InvestorNewsBreaks - SRAX Inc. (NASDAQ: SRAX) Announces Upcoming Sequire Semiconductor Conference
- Standard Lithium Ltd. (NYSE American: SLI) - InvestorNewsBreaks - Standard Lithium Ltd. (TSX.V: SLI) (NYSE American: SLI) (FRA: S5L) Moves Closer to Commercialization of First Arkansas-Based Lithium Plant
- StorEn Technologies Inc. - InvestorNewsBreaks – StorEn Technologies Inc. Recognized for Bringing Real Innovation to Vanadium Flow Batteries
- StraightUp Resources Inc. (CSE: ST) (OTCQB: STUPF) - StraightUp Resources Extends Warrant Term
- Streamlytics - InvestorNewsBreaks – Streamlytics Joins World’s Most-Trusted Enterprise Cloud Marketplace
- Sugarmade Inc. (OTC: SGMD) - InvestorNewsBreaks - Sugarmade Inc. (SGMD) Subsidiary Inks MSA for Manufacturing, Distribution Expansion
- Sustainable Green Team Ltd. (OTC: SGTM) - InvestorNewsBreaks - Sustainable Green Team Ltd. (SGTM) Secures Purchase Renewal Contract with Louisville Division of The Kroger Company (NYSE: KR)
- Sycamore Entertainment Group Inc. (OTC: SEGI) - InvestorNewsBreaks - Sycamore Entertainment Group Inc. (SEGI) Featured in Bell2Bell Podcast
- TAAT Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQX: TOBAF) - InvestorNewsBreaks - TAAT(R) Global Alternatives Inc. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) Moves to Strengthen Commercial Capabilities, Accelerate National Expansion
- The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) - InvestorNewsBreaks - The Alkaline Water Company Inc.'s (NASDAQ: WTER) (CSE: WTER) Receives Alkaline88(R) Order from Major Wholesale Club Chain
- Tingo Inc. (OTC: TMNA) - World Bank Affiliate Looks to Blockchain to Facilitate Carbon Trading
- Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) - InvestorNewsBreaks - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Partners with IMS Investor Relations for Consulting, Communications and Outreach Services
- TRxADE HEALTH, INC. (NASDAQ: MEDS) - InvestorNewsBreaks - TRxADE Health Inc. (NASDAQ: MEDS) Launches TRxADE Prime Plus to Meet Customers' Needs of On-Demand Inventory
- Uranium Energy Corp. (NYSE American: UEC) - InvestorNewsBreaks - Uranium Energy Corp. (NYSE American: UEC) Files Required Docs to Expand Wyoming ISR Project
- VistaGen Therapeutics Inc. (NASDAQ: VTGN) - InvestorNewsBreaks - VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation Schedule for Upcoming Conferences
- Vivos Therapeutics Inc. (NASDAQ: VVOS) - Vivos Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
- Wrap Technologies Inc. (NASDAQ: WRAP) - New Body Cam Footage Presents Successful Use of BolaWrap in Georgia to Help De-escalate Crisis Situation
- XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) - XPhyto Closes Final Tranche of Fully Subscribed Financing
The QualityStocks DailyNetwork Sponsors
About The QualityStocks Daily
The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.
Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.
"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.
The QualityStocks Numbers Report
QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.
The QualityStocks Sponsored News
- 180 Life Sciences Corp. (NASDAQ: ATNF) - InvestorNewsBreaks - 180 Life Sciences Corp. (NASDAQ: ATNF) Enrolls First Patient in Early-Stage Frozen Shoulder Trial
- Aditxt Inc. (NASDAQ: ADTX) - Aditxt, Inc. (Nasdaq: ADTX) Announces 1-for-50 Reverse Stock Split Effective Pre-Market Opening on September 14, 2022
- Advanced Container Technologies Inc. (OTC: ACTX) - 420 with CNW - King's College London Plans Largest Study on Marijuana
- American Cannabis Partners - 420 with CNW — California Cannabis Authority Enters Partnership with CPPC
- Amesite Inc. (NASDAQ: AMST) - InvestorNewsBreaks - Amesite Inc. (NASDAQ: AMST), NAFEO Welcome New Members to Alliance Designed to Offer Online Learning Opportunities
- AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) - AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Appeal
- AmpliTech Group Inc. (NASDAQ: AMPG) - InvestorNewsBreaks - AmpliTech Group Inc. (NASDAQ: AMPG) Releases Acquisition Update, Anticipated Results
- AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) - SUSTAINN, AREV's Ready to Use Therapeutic Foods discussed in leading article in HealthHIV
- Augmedix Inc. (NASDAQ: AUGX) - Augmedix to Participate at the 2022 Lytham Partners Fall Investor Conference
- Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) - InvestorNewsBreaks - Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Releases Q2 2022 Report
- BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) - InvestorNewsBreaks - BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) Releases Shareholder Update with Corporate, Operational Highlights
- Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) - InvestorNewsBreaks - Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) Announces Joint Agreement, Expanded Opportunity in Overseas Gaming Market
- Brain Scientific Inc. (OTCQB: BRSF) - InvestorNewsBreaks - Brain Scientific Inc. (BRSF) Secures CE Mark Approval for NeuroCap(TM)
- Cannabis Strategic Ventures Inc. (OTC: NUGS) - 420 with CNW - White House Reveals President Biden Has No Plans to Act on Cannabis Reform Ahead of Midterms
- Cerberus Cyber Sentinel Corp. (NASDAQ: CISO) - InvestorNewsBreaks - Cerberus Cyber Sentinel Corp. (NASDAQ: CISO) Appoints Seasoned Veteran as M&A Legal Counsel
- CNS Pharmaceuticals Inc. (NASDAQ: CNSP) - Focused Ultrasound May Offer Easier Way to Treat Brain Tumors Effectively
- Correlate Infrastructure Partners Inc. (OTCQB: CIPI) - Correlate Infrastructure Partners Inc. (CIPI) Teams with CEA Lighting Distributor UYS to Boost Indoor Horticulture Services
- Cub Crafters Inc. - CubCrafters Inc.’s Popularity is Displayed by Quick Response to its Pending Public Offering, while the Backcountry Aircraft Manufacturer Awaits SEC Qualification
- Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) - Study Suggests Reported Psychedelics Microdosing Effects Are Due to User Expectancy
- DarioHealth Corp. (NASDAQ: DRIO) - InvestorNewsBreaks - DarioHealth Corp. (NASDAQ: DRIO) Releases Q2 2022 Financial Report, Corporate Update
- DealMaker - InvestorNewsBreaks – DealMaker CEO Featured on ‘Gamechangers LIVE’
- D-Wave Quantum Inc. (NYSE: QBTS) - D-Wave Demonstrates Large-Scale Coherent Quantum Annealing
- Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) - Congressman Says Lawmakers' Reluctance Regarding Psychedelic Therapy Is Embarrassing
- DSG Global Inc. (OTCQB: DSGT) - InvestorNewsBreaks - DSG Global Inc. (DSGT) Secures ICON Capital Group as Financial Advisor to Pursue Strategic Spinout
- Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF) - Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF) Welcomes Plant-based Industry Pioneer and former Director of Beyond Meat to Advisory Board Amid Ramp-up of Healthful Food Innovations, Distribution
- Strong Earnings, Revenue Reports from Plant-based Foods Maker Belle Pulses, Drives Cheery Assessment for Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF)
- ESGBreaks - Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF) Lays Strong Foundation in 'Seed-to-Market' Approach
- Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) - Power Conversion Innovation May Boost Power Plant Efficiency
- Exro Technologies Inc. (TSX: EXRO) (OTCQB: EXROF) - Exro Announces Closing of Brokered Public Offering and Update on Concurrent Non-Brokered Private Placement
- FingerMotion Inc. (NASDAQ: FNGR) - FingerMotion Inc. (NASDAQ: FNGR) Upgrades to Sapientus Analytics Division Hone in on Tech Tool Trends in China
- First Energy Metals Ltd. (CSE: FE) (OTCQB: FEMFF) - InvestorNewsBreaks - First Energy Metals Ltd. (CSE: FE) (OTCQB: FEMFF) (WKN: A2JC89) Options Two Lithium Claims Directly Adjacent to 'Electric Avenue'
- Flora Growth Corp. (NASDAQ: FLGC) - 420 with CNW - Four Novel Ways in Which Hemp Can Be Used Today
- Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX) - InvestorNewsBreaks - Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX) Investor Conference Presentation Available on Company Website
- Freight Technologies Inc. (NASDAQ: FRGT) - Freight Technologies Inc. (NASDAQ: FRGT) Marks Milestone Intended to Foster Company Growth
- Friendable Inc. (FDBL) - As Congress Looks to Change How Streaming Services Pay Musicians, Friendable Inc. (FDBL) Offers Viable Solution with 360-Degree Platform Supporting Music Artist Production, Distribution, and Marketing
- FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) - InvestorNewsBreaks - FuelPositive Corporation (TSX.V: NHHH) (OTCQB: NHHHF) to Present at H.C. Wainwright 24th Global Investment Conference
- GeoSolar Technologies Inc. - GeoSolar Technologies Inc. Offers Potentially Ground-Breaking Solution as the World Goes Through Arguably Most Important Transition Ever
- Golden Matrix Group Inc. (NASDAQ: GMGI) - InvestorNewsBreaks - Golden Matrix Group Inc. (NASDAQ: GMGI) Achieves Record Revenues, 16th Consecutive Quarter of Profitability
- Golden Triangle Ventures Inc. (OTC: GTVH) - InvestorNewsBreaks - Golden Triangle Ventures Inc. (GTVH) Appoints New Global Health Services CEO
- Genprex Inc. (NASDAQ: GNPX) - InvestorNewsBreaks - Genprex Inc. (NASDAQ: GNPX) CFO to Present Pioneering Gene Therapies at Upcoming Conference
- Green Hygienics Holdings Inc. (OTCQB: GRYN) - InvestorNewsBreaks - Green Hygienics Holdings Inc. (GRYN) Enters US Plant-Based Food Market with Superior Hemp Protein Product
- GreenBox POS (NASDAQ: GBOX) - InvestorNewsBreaks - GreenBox POS (NASDAQ: GBOX) to Present at 24th Annual H.C. Wainwright Global Investment Conference
- HeartBeam Inc. (NASDAQ: BEAT) - InvestorNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) Secures Additional IP Protection for Breakthrough ECG Patch Technology
- Cepton Inc. (NASDAQ: CPTN) - Cepton, Inc. (NASDAQ: CPTN) - Experts Confirm Lidar Technology Provides Superior Automotive Safety Compared to Camera-only Systems
- Hemptown USA - InvestorNewsBreaks - Hero Technologies Inc. (HENC) Common Stock Upgraded to Mid-Tier OTC Equity Market
- Hero Technologies Inc. (OTC: HENC) - InvestorNewsBreaks - Hero Technologies (HENC) Looking to Acquire Land to Serve as Basis for Growing Cannabis Business
- Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F) - Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA) at the Wheel as EV Evolution Shifts into Next Gear
- Home Bistro Inc. (OTC: HBIS) - InvestorNewsBreaks - Home Bistro Inc. (HBIS) Announces Q3 2022 Financial Results
- iClick Interactive Asia Group Ltd. (NASDAQ: ICLK) - InvestorNewsBreaks - iClick Interactive Asia Group Limited (NASDAQ: ICLK) Announces Q2 2022 Unaudited Financial Results
- Ideanomics Inc. (NASDAQ: IDEX) - InvestorNewsBreaks - Ideanomics Inc. (NASDAQ: IDEX), ABC Companies Partner to Expand Distribution of Exclusive WAVE Wireless Charging Solutions
- Infobird Co., Ltd (NASDAQ: IFBD) - InvestorNewsBreaks - Infobird Co. Ltd. (NASDAQ: IFBD) Partners with Global Multinational Enterprise for 'Customer Win' and Food-Service Distribution Milestone
- InMed Pharmaceuticals Inc. (NASDAQ: INM) - InvestorNewsBreaks - InMed Pharmaceuticals Inc. (NASDAQ: INM) Closes $6M Private Placement Agreement
- InnerScope Hearing Technologies Inc. (OTC: INND) - InvestorNewsBreaks - InnerScope Hearing Technologies Inc. (INND) Announces Completion of 2019, 2020 Audited Financial Statements
- Innovative Payment Solutions Inc. (OTCQB: IPSI) - Innovative Payment Solutions, Inc. Appoints Richard Rosenblum as President and Chief Financial Officer
- BlockQuarry Corp. (OTC: BLQC) - Interoperability Crucial to Mass Adoption of Blockchain Technology
- Knightscope (NASDAQ: KSCP) - InvestorNewsBreaks - Knightscope Inc. (NASDAQ: KSCP) Secures Expanded Contract with Oregon-Based Client
- Kronos Advanced Technologies Inc. (OTC: KNOS) - InvestorNewsBreaks - Kronos Advanced Technologies Inc. (KNOS) Positioned Amid Expected Growth of Indoor Air Quality Market
- Laredo Oil Inc. (OTC: LRDC) - ESGBreaks - Laredo Oil Inc. (LRDC) Ideally Poised as Bullish 2023 Forecast Suggests Pricing Uptrend
- Lexaria Bioscience Corp. (NASDAQ: LEXX) - CannabisNewsBreaks - Lexaria Bioscience Corp.'s (NASDAQ: LEXX) Hypertension Treatment Program Stands Distinct
- Lottery.com Inc. (NASDAQ: LTRY) - InvestorNewsBreaks - Lottery.com (NASDAQ: LTRY) Releases Q1 Financial, Operational Results
- LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) - CryptoNewsBreaks - LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) at Forefront to Implement Cryptocurrency as Viable Monetary Solution
- LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) Leverages Over 30 BTC Capacity and 300 Channels Across 17 Countries on Lightning Network
- CryptoNewsBreaks - LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) Eyes Lightning Growth with >56K Transactions and Counting
- MedSmart Group Inc. (OTC: MSGP) - InvestorNewsBreaks - MedSmart Group Inc. (MSGP) Announces Milanion Limited's Inroads into Ukraine Through Strategic MOU
- Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) - MINDCURE Announces Financial Results for Fiscal 2022
- Mobius Interactive Ltd. - InvestorNewsBreaks – Mobius Interactive Ltd.’s Mobius.bet Poised in Lucrative Emerging Market
- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) - InvestorNewsBreaks - Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Files Prospectus Supplement, Closes First Tranche Under Subscription Agreement
- Nemaura Medical Inc. (NASDAQ: NMRD) - InvestorNewsBreaks - Nemaura Medical Inc. (NASDAQ: NMRD) Announces Participation at Upcoming H.C. Wainwright Global Investment Conference
- Mullen Automotive Inc. (NASDAQ: MULN) - InvestorNewsBreaks - Mullen Automotive Inc. (NASDAQ: MULN) Provides First Look at Its Ultra-High-Performance FIVE RS
- Nexstar Media Group Inc. (NASDAQ: NXST) - InvestorNewsBreaks - Nexstar Media Group Inc. (NASDAQ: NXST) Announces 17th Market to Launch ATSC 3.0 This Year
- Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF) - InvestorNewsBreaks - Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF) (FSE: N29) Appoints New CEO to Take 'Map D' to next Level of Growth
- Nowigence Inc. (OTCQB: NOWG) - Nowigence Inc. (NOWG) Starts Trading on OTC
- Odyssey Group International Inc. (OTC: ODYY) - Odyssey Health, Inc.'s (ODYY) PRV-002 Drug Candidate Designed to Immediately Mitigate the Effects of Concussion on Brain Function
- PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) - InvestorNewsBreaks - PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) Announces Distribution Agreement to Expand Little West Cold Pressed Juices Footprint
- Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF) - InvestorNewsBreaks - Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF) (FSE: 7CR) Inks Licensing, Distribution Agreement with Global iGaming Aggregator
- PowerTap Hydrogen Capital Corp. (NEO: MOVE) (FWB: 2K6A) (OTC: MOTNF) - InvestorNewsBreaks - PowerTap Hydrogen Capital Corp. (NEO: MOVE) (OTC: MOTNF) (FWB: 2K6) Engages T2M for Rapid Deployment of Gen3 Hydrogen Unit
- Predictive Oncology (NASDAQ: POAI) - InvestorNewsBreaks - Predictive Oncology Inc. (NASDAQ: POAI) Releases Q2 Financial Report
- Pressure BioSciences Inc. (PBIO) - InvestorNewsBreaks - Pressure BioSciences Inc. (PBIO) Announces Participation at H. C. Wainwright Annual Global Investment Conference
- Prime Harvest Inc. - 420 with CNW — Director of Federal Health Agency Blasts Cannabis Research Barriers Impeding Opioid Research
- Processa Pharmaceuticals Inc. (NASDAQ: PCSA) - InvestorNewsBreaks - Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Shares Update on Clinical Programs Enrollment
- QSAM Biosciences Inc. (OTCQB: QSAM) - Researchers Find Cases of Osteosarcoma More Prevalent in Blacks
- Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) - Top Marijuana Penny Stocks Right Now? 3 For Your List In September
- Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF) - Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF) Is 'One to Watch'
- REZYFi, Inc. - InvestorNewsBreaks – REZYFi Inc. Engages IBN for Corporate Communications Expertise
- RYAH Group Inc. (CSE: RYAH) - InvestorNewsBreaks – RYAH Group Inc. (CSE: RYAH) Announces Industry Veteran as New VP Overseeing IP Commercialization
- Sanwire Corp. (SNWR) - InvestorNewsBreaks - Sanwire Corporation (SNWR) Subsidiary Releases Q2 Financial Results, Corporate Update
- Save Foods Inc. (NASDAQ: SVFD) - InvestorNewsBreaks - Save Foods Inc. (NASDAQ: SVFD) Sees New Customer Growth as Mexican Lime Producers Adopt Protection Treatment
- Sharing Services Global Corporation (SHRG) - InvestorNewsBreaks - Sharing Services Global Corporation (SHRG) Announces Official Launch Event for Hapi Travel
- Sigma Additive Solutions (NASDAQ: SASI) - InvestorNewsBreaks - Sigma Additive Solutions (NASDAQ: SASI) Announces Q2 2022 Financial Results
- Silo Pharma Inc. (OTCQB: SILO) - InvestorNewsBreaks - Silo Pharma Inc. (SILOD) Implements Reverse Stock Split in Preparation for Nasdaq Uplisting
- Siyata Mobile Inc. (NASDAQ: SYTA) (TSXV: SIM) - InvestorNewsBreaks - Siyata Mobile Inc. (NASDAQ: SYTA) Integrates SD7 with CrisisGo Panic App to Improve Crisis Communication Between Teachers, First Responders
- Simply Sonoma Inc. - InvestorNewsBreaks – Simply Sonoma Enters Growing CBD-Infused Beverages Space
- Splash Beverage Group Inc. (NYSE American: SBEV) - InvestorNewsBreaks - Splash Beverage Group Inc. (NYSE American: SBEV) Finalizes Distribution Agreements in Nevada, Maryland for SALT Tequila Brand
- SPYR Inc. (OTCQB: SPYR) - InvestorNewsBreaks - SPYR Inc. (SPYR) Subsidiary Patented Platform Provides Smart Solutions for Simple IoT Problems
- SRAX Inc. (NASDAQ: SRAX) - InvestorNewsBreaks - SRAX Inc. (NASDAQ: SRAX) Announces Upcoming Sequire Semiconductor Conference
- Standard Lithium Ltd. (NYSE American: SLI) - InvestorNewsBreaks - Standard Lithium Ltd. (TSX.V: SLI) (NYSE American: SLI) (FRA: S5L) Moves Closer to Commercialization of First Arkansas-Based Lithium Plant
- StorEn Technologies Inc. - InvestorNewsBreaks – StorEn Technologies Inc. Recognized for Bringing Real Innovation to Vanadium Flow Batteries
- StraightUp Resources Inc. (CSE: ST) (OTCQB: STUPF) - StraightUp Resources Extends Warrant Term
- Streamlytics - InvestorNewsBreaks – Streamlytics Joins World’s Most-Trusted Enterprise Cloud Marketplace
- Sugarmade Inc. (OTC: SGMD) - InvestorNewsBreaks - Sugarmade Inc. (SGMD) Subsidiary Inks MSA for Manufacturing, Distribution Expansion
- Sustainable Green Team Ltd. (OTC: SGTM) - InvestorNewsBreaks - Sustainable Green Team Ltd. (SGTM) Secures Purchase Renewal Contract with Louisville Division of The Kroger Company (NYSE: KR)
- Sycamore Entertainment Group Inc. (OTC: SEGI) - InvestorNewsBreaks - Sycamore Entertainment Group Inc. (SEGI) Featured in Bell2Bell Podcast
- TAAT Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQX: TOBAF) - InvestorNewsBreaks - TAAT(R) Global Alternatives Inc. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) Moves to Strengthen Commercial Capabilities, Accelerate National Expansion
- The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) - InvestorNewsBreaks - The Alkaline Water Company Inc.'s (NASDAQ: WTER) (CSE: WTER) Receives Alkaline88(R) Order from Major Wholesale Club Chain
- Tingo Inc. (OTC: TMNA) - World Bank Affiliate Looks to Blockchain to Facilitate Carbon Trading
- Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) - InvestorNewsBreaks - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Partners with IMS Investor Relations for Consulting, Communications and Outreach Services
- TRxADE HEALTH, INC. (NASDAQ: MEDS) - InvestorNewsBreaks - TRxADE Health Inc. (NASDAQ: MEDS) Launches TRxADE Prime Plus to Meet Customers' Needs of On-Demand Inventory
- Uranium Energy Corp. (NYSE American: UEC) - InvestorNewsBreaks - Uranium Energy Corp. (NYSE American: UEC) Files Required Docs to Expand Wyoming ISR Project
- VistaGen Therapeutics Inc. (NASDAQ: VTGN) - InvestorNewsBreaks - VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation Schedule for Upcoming Conferences
- Vivos Therapeutics Inc. (NASDAQ: VVOS) - Vivos Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
- Wrap Technologies Inc. (NASDAQ: WRAP) - New Body Cam Footage Presents Successful Use of BolaWrap in Georgia to Help De-escalate Crisis Situation
- XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) - XPhyto Closes Final Tranche of Fully Subscribed Financing
The QualityStocks DailyNetwork Sponsors
About The QualityStocks Daily
The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.
Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.
"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.
The QualityStocks Numbers Report
QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.
The QualityStocks Sponsored News
- 180 Life Sciences Corp. (NASDAQ: ATNF) - InvestorNewsBreaks - 180 Life Sciences Corp. (NASDAQ: ATNF) Enrolls First Patient in Early-Stage Frozen Shoulder Trial
- Aditxt Inc. (NASDAQ: ADTX) - Aditxt, Inc. (Nasdaq: ADTX) Announces 1-for-50 Reverse Stock Split Effective Pre-Market Opening on September 14, 2022
- Advanced Container Technologies Inc. (OTC: ACTX) - 420 with CNW - King's College London Plans Largest Study on Marijuana
- American Cannabis Partners - 420 with CNW — California Cannabis Authority Enters Partnership with CPPC
- Amesite Inc. (NASDAQ: AMST) - InvestorNewsBreaks - Amesite Inc. (NASDAQ: AMST), NAFEO Welcome New Members to Alliance Designed to Offer Online Learning Opportunities
- AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) - AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Appeal
- AmpliTech Group Inc. (NASDAQ: AMPG) - InvestorNewsBreaks - AmpliTech Group Inc. (NASDAQ: AMPG) Releases Acquisition Update, Anticipated Results
- AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) - SUSTAINN, AREV's Ready to Use Therapeutic Foods discussed in leading article in HealthHIV
- Augmedix Inc. (NASDAQ: AUGX) - Augmedix to Participate at the 2022 Lytham Partners Fall Investor Conference
- Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) - InvestorNewsBreaks - Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Releases Q2 2022 Report
- BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) - InvestorNewsBreaks - BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) Releases Shareholder Update with Corporate, Operational Highlights
- Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) - InvestorNewsBreaks - Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) Announces Joint Agreement, Expanded Opportunity in Overseas Gaming Market
- Brain Scientific Inc. (OTCQB: BRSF) - InvestorNewsBreaks - Brain Scientific Inc. (BRSF) Secures CE Mark Approval for NeuroCap(TM)
- Cannabis Strategic Ventures Inc. (OTC: NUGS) - 420 with CNW - White House Reveals President Biden Has No Plans to Act on Cannabis Reform Ahead of Midterms
- Cerberus Cyber Sentinel Corp. (NASDAQ: CISO) - InvestorNewsBreaks - Cerberus Cyber Sentinel Corp. (NASDAQ: CISO) Appoints Seasoned Veteran as M&A Legal Counsel
- CNS Pharmaceuticals Inc. (NASDAQ: CNSP) - Focused Ultrasound May Offer Easier Way to Treat Brain Tumors Effectively
- Correlate Infrastructure Partners Inc. (OTCQB: CIPI) - Correlate Infrastructure Partners Inc. (CIPI) Teams with CEA Lighting Distributor UYS to Boost Indoor Horticulture Services
- Cub Crafters Inc. - CubCrafters Inc.’s Popularity is Displayed by Quick Response to its Pending Public Offering, while the Backcountry Aircraft Manufacturer Awaits SEC Qualification
- Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) - Study Suggests Reported Psychedelics Microdosing Effects Are Due to User Expectancy
- DarioHealth Corp. (NASDAQ: DRIO) - InvestorNewsBreaks - DarioHealth Corp. (NASDAQ: DRIO) Releases Q2 2022 Financial Report, Corporate Update
- DealMaker - InvestorNewsBreaks – DealMaker CEO Featured on ‘Gamechangers LIVE’
- D-Wave Quantum Inc. (NYSE: QBTS) - D-Wave Demonstrates Large-Scale Coherent Quantum Annealing
- Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) - Congressman Says Lawmakers' Reluctance Regarding Psychedelic Therapy Is Embarrassing
- DSG Global Inc. (OTCQB: DSGT) - InvestorNewsBreaks - DSG Global Inc. (DSGT) Secures ICON Capital Group as Financial Advisor to Pursue Strategic Spinout
- Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF) - Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF) Welcomes Plant-based Industry Pioneer and former Director of Beyond Meat to Advisory Board Amid Ramp-up of Healthful Food Innovations, Distribution
- Strong Earnings, Revenue Reports from Plant-based Foods Maker Belle Pulses, Drives Cheery Assessment for Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF)
- ESGBreaks - Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF) Lays Strong Foundation in 'Seed-to-Market' Approach
- Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) - Power Conversion Innovation May Boost Power Plant Efficiency
- Exro Technologies Inc. (TSX: EXRO) (OTCQB: EXROF) - Exro Announces Closing of Brokered Public Offering and Update on Concurrent Non-Brokered Private Placement
- FingerMotion Inc. (NASDAQ: FNGR) - FingerMotion Inc. (NASDAQ: FNGR) Upgrades to Sapientus Analytics Division Hone in on Tech Tool Trends in China
- First Energy Metals Ltd. (CSE: FE) (OTCQB: FEMFF) - InvestorNewsBreaks - First Energy Metals Ltd. (CSE: FE) (OTCQB: FEMFF) (WKN: A2JC89) Options Two Lithium Claims Directly Adjacent to 'Electric Avenue'
- Flora Growth Corp. (NASDAQ: FLGC) - 420 with CNW - Four Novel Ways in Which Hemp Can Be Used Today
- Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX) - InvestorNewsBreaks - Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX) Investor Conference Presentation Available on Company Website
- Freight Technologies Inc. (NASDAQ: FRGT) - Freight Technologies Inc. (NASDAQ: FRGT) Marks Milestone Intended to Foster Company Growth
- Friendable Inc. (FDBL) - As Congress Looks to Change How Streaming Services Pay Musicians, Friendable Inc. (FDBL) Offers Viable Solution with 360-Degree Platform Supporting Music Artist Production, Distribution, and Marketing
- FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) - InvestorNewsBreaks - FuelPositive Corporation (TSX.V: NHHH) (OTCQB: NHHHF) to Present at H.C. Wainwright 24th Global Investment Conference
- GeoSolar Technologies Inc. - GeoSolar Technologies Inc. Offers Potentially Ground-Breaking Solution as the World Goes Through Arguably Most Important Transition Ever
- Golden Matrix Group Inc. (NASDAQ: GMGI) - InvestorNewsBreaks - Golden Matrix Group Inc. (NASDAQ: GMGI) Achieves Record Revenues, 16th Consecutive Quarter of Profitability
- Golden Triangle Ventures Inc. (OTC: GTVH) - InvestorNewsBreaks - Golden Triangle Ventures Inc. (GTVH) Appoints New Global Health Services CEO
- Genprex Inc. (NASDAQ: GNPX) - InvestorNewsBreaks - Genprex Inc. (NASDAQ: GNPX) CFO to Present Pioneering Gene Therapies at Upcoming Conference
- Green Hygienics Holdings Inc. (OTCQB: GRYN) - InvestorNewsBreaks - Green Hygienics Holdings Inc. (GRYN) Enters US Plant-Based Food Market with Superior Hemp Protein Product
- GreenBox POS (NASDAQ: GBOX) - InvestorNewsBreaks - GreenBox POS (NASDAQ: GBOX) to Present at 24th Annual H.C. Wainwright Global Investment Conference
- HeartBeam Inc. (NASDAQ: BEAT) - InvestorNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) Secures Additional IP Protection for Breakthrough ECG Patch Technology
- Cepton Inc. (NASDAQ: CPTN) - Cepton, Inc. (NASDAQ: CPTN) - Experts Confirm Lidar Technology Provides Superior Automotive Safety Compared to Camera-only Systems
- Hemptown USA - InvestorNewsBreaks - Hero Technologies Inc. (HENC) Common Stock Upgraded to Mid-Tier OTC Equity Market
- Hero Technologies Inc. (OTC: HENC) - InvestorNewsBreaks - Hero Technologies (HENC) Looking to Acquire Land to Serve as Basis for Growing Cannabis Business
- Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F) - Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA) at the Wheel as EV Evolution Shifts into Next Gear
- Home Bistro Inc. (OTC: HBIS) - InvestorNewsBreaks - Home Bistro Inc. (HBIS) Announces Q3 2022 Financial Results
- iClick Interactive Asia Group Ltd. (NASDAQ: ICLK) - InvestorNewsBreaks - iClick Interactive Asia Group Limited (NASDAQ: ICLK) Announces Q2 2022 Unaudited Financial Results
- Ideanomics Inc. (NASDAQ: IDEX) - InvestorNewsBreaks - Ideanomics Inc. (NASDAQ: IDEX), ABC Companies Partner to Expand Distribution of Exclusive WAVE Wireless Charging Solutions
- Infobird Co., Ltd (NASDAQ: IFBD) - InvestorNewsBreaks - Infobird Co. Ltd. (NASDAQ: IFBD) Partners with Global Multinational Enterprise for 'Customer Win' and Food-Service Distribution Milestone
- InMed Pharmaceuticals Inc. (NASDAQ: INM) - InvestorNewsBreaks - InMed Pharmaceuticals Inc. (NASDAQ: INM) Closes $6M Private Placement Agreement
- InnerScope Hearing Technologies Inc. (OTC: INND) - InvestorNewsBreaks - InnerScope Hearing Technologies Inc. (INND) Announces Completion of 2019, 2020 Audited Financial Statements
- Innovative Payment Solutions Inc. (OTCQB: IPSI) - Innovative Payment Solutions, Inc. Appoints Richard Rosenblum as President and Chief Financial Officer
- BlockQuarry Corp. (OTC: BLQC) - Interoperability Crucial to Mass Adoption of Blockchain Technology
- Knightscope (NASDAQ: KSCP) - InvestorNewsBreaks - Knightscope Inc. (NASDAQ: KSCP) Secures Expanded Contract with Oregon-Based Client
- Kronos Advanced Technologies Inc. (OTC: KNOS) - InvestorNewsBreaks - Kronos Advanced Technologies Inc. (KNOS) Positioned Amid Expected Growth of Indoor Air Quality Market
- Laredo Oil Inc. (OTC: LRDC) - ESGBreaks - Laredo Oil Inc. (LRDC) Ideally Poised as Bullish 2023 Forecast Suggests Pricing Uptrend
- Lexaria Bioscience Corp. (NASDAQ: LEXX) - CannabisNewsBreaks - Lexaria Bioscience Corp.'s (NASDAQ: LEXX) Hypertension Treatment Program Stands Distinct
- Lottery.com Inc. (NASDAQ: LTRY) - InvestorNewsBreaks - Lottery.com (NASDAQ: LTRY) Releases Q1 Financial, Operational Results
- LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) - CryptoNewsBreaks - LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) at Forefront to Implement Cryptocurrency as Viable Monetary Solution
- LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) Leverages Over 30 BTC Capacity and 300 Channels Across 17 Countries on Lightning Network
- CryptoNewsBreaks - LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) Eyes Lightning Growth with >56K Transactions and Counting
- MedSmart Group Inc. (OTC: MSGP) - InvestorNewsBreaks - MedSmart Group Inc. (MSGP) Announces Milanion Limited's Inroads into Ukraine Through Strategic MOU
- Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) - MINDCURE Announces Financial Results for Fiscal 2022
- Mobius Interactive Ltd. - InvestorNewsBreaks – Mobius Interactive Ltd.’s Mobius.bet Poised in Lucrative Emerging Market
- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) - InvestorNewsBreaks - Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Files Prospectus Supplement, Closes First Tranche Under Subscription Agreement
- Nemaura Medical Inc. (NASDAQ: NMRD) - InvestorNewsBreaks - Nemaura Medical Inc. (NASDAQ: NMRD) Announces Participation at Upcoming H.C. Wainwright Global Investment Conference
- Mullen Automotive Inc. (NASDAQ: MULN) - InvestorNewsBreaks - Mullen Automotive Inc. (NASDAQ: MULN) Provides First Look at Its Ultra-High-Performance FIVE RS
- Nexstar Media Group Inc. (NASDAQ: NXST) - InvestorNewsBreaks - Nexstar Media Group Inc. (NASDAQ: NXST) Announces 17th Market to Launch ATSC 3.0 This Year
- Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF) - InvestorNewsBreaks - Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF) (FSE: N29) Appoints New CEO to Take 'Map D' to next Level of Growth
- Nowigence Inc. (OTCQB: NOWG) - Nowigence Inc. (NOWG) Starts Trading on OTC
- Odyssey Group International Inc. (OTC: ODYY) - Odyssey Health, Inc.'s (ODYY) PRV-002 Drug Candidate Designed to Immediately Mitigate the Effects of Concussion on Brain Function
- PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) - InvestorNewsBreaks - PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) Announces Distribution Agreement to Expand Little West Cold Pressed Juices Footprint
- Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF) - InvestorNewsBreaks - Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF) (FSE: 7CR) Inks Licensing, Distribution Agreement with Global iGaming Aggregator
- PowerTap Hydrogen Capital Corp. (NEO: MOVE) (FWB: 2K6A) (OTC: MOTNF) - InvestorNewsBreaks - PowerTap Hydrogen Capital Corp. (NEO: MOVE) (OTC: MOTNF) (FWB: 2K6) Engages T2M for Rapid Deployment of Gen3 Hydrogen Unit
- Predictive Oncology (NASDAQ: POAI) - InvestorNewsBreaks - Predictive Oncology Inc. (NASDAQ: POAI) Releases Q2 Financial Report
- Pressure BioSciences Inc. (PBIO) - InvestorNewsBreaks - Pressure BioSciences Inc. (PBIO) Announces Participation at H. C. Wainwright Annual Global Investment Conference
- Prime Harvest Inc. - 420 with CNW — Director of Federal Health Agency Blasts Cannabis Research Barriers Impeding Opioid Research
- Processa Pharmaceuticals Inc. (NASDAQ: PCSA) - InvestorNewsBreaks - Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Shares Update on Clinical Programs Enrollment
- QSAM Biosciences Inc. (OTCQB: QSAM) - Researchers Find Cases of Osteosarcoma More Prevalent in Blacks
- Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) - Top Marijuana Penny Stocks Right Now? 3 For Your List In September
- Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF) - Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF) Is 'One to Watch'
- REZYFi, Inc. - InvestorNewsBreaks – REZYFi Inc. Engages IBN for Corporate Communications Expertise
- RYAH Group Inc. (CSE: RYAH) - InvestorNewsBreaks – RYAH Group Inc. (CSE: RYAH) Announces Industry Veteran as New VP Overseeing IP Commercialization
- Sanwire Corp. (SNWR) - InvestorNewsBreaks - Sanwire Corporation (SNWR) Subsidiary Releases Q2 Financial Results, Corporate Update
- Save Foods Inc. (NASDAQ: SVFD) - InvestorNewsBreaks - Save Foods Inc. (NASDAQ: SVFD) Sees New Customer Growth as Mexican Lime Producers Adopt Protection Treatment
- Sharing Services Global Corporation (SHRG) - InvestorNewsBreaks - Sharing Services Global Corporation (SHRG) Announces Official Launch Event for Hapi Travel
- Sigma Additive Solutions (NASDAQ: SASI) - InvestorNewsBreaks - Sigma Additive Solutions (NASDAQ: SASI) Announces Q2 2022 Financial Results
- Silo Pharma Inc. (OTCQB: SILO) - InvestorNewsBreaks - Silo Pharma Inc. (SILOD) Implements Reverse Stock Split in Preparation for Nasdaq Uplisting
- Siyata Mobile Inc. (NASDAQ: SYTA) (TSXV: SIM) - InvestorNewsBreaks - Siyata Mobile Inc. (NASDAQ: SYTA) Integrates SD7 with CrisisGo Panic App to Improve Crisis Communication Between Teachers, First Responders
- Simply Sonoma Inc. - InvestorNewsBreaks – Simply Sonoma Enters Growing CBD-Infused Beverages Space
- Splash Beverage Group Inc. (NYSE American: SBEV) - InvestorNewsBreaks - Splash Beverage Group Inc. (NYSE American: SBEV) Finalizes Distribution Agreements in Nevada, Maryland for SALT Tequila Brand
- SPYR Inc. (OTCQB: SPYR) - InvestorNewsBreaks - SPYR Inc. (SPYR) Subsidiary Patented Platform Provides Smart Solutions for Simple IoT Problems
- SRAX Inc. (NASDAQ: SRAX) - InvestorNewsBreaks - SRAX Inc. (NASDAQ: SRAX) Announces Upcoming Sequire Semiconductor Conference
- Standard Lithium Ltd. (NYSE American: SLI) - InvestorNewsBreaks - Standard Lithium Ltd. (TSX.V: SLI) (NYSE American: SLI) (FRA: S5L) Moves Closer to Commercialization of First Arkansas-Based Lithium Plant
- StorEn Technologies Inc. - InvestorNewsBreaks – StorEn Technologies Inc. Recognized for Bringing Real Innovation to Vanadium Flow Batteries
- StraightUp Resources Inc. (CSE: ST) (OTCQB: STUPF) - StraightUp Resources Extends Warrant Term
- Streamlytics - InvestorNewsBreaks – Streamlytics Joins World’s Most-Trusted Enterprise Cloud Marketplace
- Sugarmade Inc. (OTC: SGMD) - InvestorNewsBreaks - Sugarmade Inc. (SGMD) Subsidiary Inks MSA for Manufacturing, Distribution Expansion
- Sustainable Green Team Ltd. (OTC: SGTM) - InvestorNewsBreaks - Sustainable Green Team Ltd. (SGTM) Secures Purchase Renewal Contract with Louisville Division of The Kroger Company (NYSE: KR)
- Sycamore Entertainment Group Inc. (OTC: SEGI) - InvestorNewsBreaks - Sycamore Entertainment Group Inc. (SEGI) Featured in Bell2Bell Podcast
- TAAT Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQX: TOBAF) - InvestorNewsBreaks - TAAT(R) Global Alternatives Inc. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) Moves to Strengthen Commercial Capabilities, Accelerate National Expansion
- The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) - InvestorNewsBreaks - The Alkaline Water Company Inc.'s (NASDAQ: WTER) (CSE: WTER) Receives Alkaline88(R) Order from Major Wholesale Club Chain
- Tingo Inc. (OTC: TMNA) - World Bank Affiliate Looks to Blockchain to Facilitate Carbon Trading
- Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) - InvestorNewsBreaks - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Partners with IMS Investor Relations for Consulting, Communications and Outreach Services
- TRxADE HEALTH, INC. (NASDAQ: MEDS) - InvestorNewsBreaks - TRxADE Health Inc. (NASDAQ: MEDS) Launches TRxADE Prime Plus to Meet Customers' Needs of On-Demand Inventory
- Uranium Energy Corp. (NYSE American: UEC) - InvestorNewsBreaks - Uranium Energy Corp. (NYSE American: UEC) Files Required Docs to Expand Wyoming ISR Project
- VistaGen Therapeutics Inc. (NASDAQ: VTGN) - InvestorNewsBreaks - VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation Schedule for Upcoming Conferences
- Vivos Therapeutics Inc. (NASDAQ: VVOS) - Vivos Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
- Wrap Technologies Inc. (NASDAQ: WRAP) - New Body Cam Footage Presents Successful Use of BolaWrap in Georgia to Help De-escalate Crisis Situation
- XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) - XPhyto Closes Final Tranche of Fully Subscribed Financing
The QualityStocks DailyNetwork Sponsors
About The QualityStocks Daily
The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.
Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.
"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.